# 2025年12月25日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 血管炎性筋膜炎表征具有干扰素-γ特征的血管炎性肌病的一个独特亚型

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41441888)
**期刊：** Acta neuropathologica
**PMID：** 41441888
**DOI：** 10.1007/s00401-025-02969-1

### 第一部分 原文与翻译

**英文原标题：** Vasculitic fasciitis characterizes a distinct subset of vasculitic myopathy with interferon-gamma signature.

> **英文摘要：**
> Vasculitic myopathy (VM) represents a nonspecific manifestation of various vasculitic syndromes that presents with myalgia, leg tenderness, and muscle weakness. Most cases of VM develop in the context of polyarteritis nodosa (PAN), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, or rheumatoid vasculitis, or manifest as single organ vasculitis. Muscle inflammation in VM is poorly understood, and most studies essentially report the presence of vasculitic changes demonstrated by microscopic analysis of skeletal muscle tissue. However, no detailed characterization or in-depth analyses have been performed so far. We studied the clinicopathologic phenotype of 12 patients and analyzed the gene expression profiles of 36 patients with VM in the context of negative ANCA test results. ANCA-negative VM typically presents with myalgia involving the lower extremities, accompanied by cutaneous manifestations, constitutional symptoms, and marked systemic inflammation. Half of the patients (6/12; 50.0%) met the classification criteria for 'classic PAN'. Serum creatine kinase (CK) activity was normal in most cases (10/12; 83.3%). The presence of skeletal muscle vasculitis was confirmed by histopathology in 9/12 (75.0%) cases. Specifically, ANCA-negative VM predominantly affected small arteries and was consistently associated with small vessel involvement of the epimysial fascia (9/10; 90.0%), which was termed 'vasculitic fasciitis' (VF). Signs of necrotizing vasculitis were occasionally noted (3/9; 33.3%). Mild endomysial fibrosis and muscle fiber necrosis could be compatible with a rather acute disease onset and may account for normal or slightly elevated levels of serum CK activity, respectively. Additionally, nonspecific myopathic changes such as capillary vessel mural thickening and variations of muscle fiber size were detected in all analyzed muscle biopsy specimens. Immunohistochemical studies revealed perifocal sarcolemmal upregulation of major histocompatibility complex class I in the majority of cases (10/11; 90.9%). RNA sequencing of muscle biopsies from 36 ANCA-negative VM patients, compared to 37 healthy controls and 649 samples from other inflammatory myopathies, revealed that ANCA-negative VM is characterized by a dominant interferon-gamma-driven immune response, broad cytokine activation including tumor necrosis factor-related genes, and selective upregulation of angiogenesis- and endothelium-associated transcripts. Our histomorphologic analysis highlights a distinct histopathological pattern of VF that is characteristic for muscle involvement in ANCA-negative vasculitis. Furthermore, we provide evidence for a specific molecular signature that gives new insights into the pathogenesis and treatment of ANCA-negative VM.

> **中文摘要：**
> 血管炎性肌病（VM）是多种血管炎综合征的一种非特异性表现，其临床特征包括肌痛、小腿压痛和肌无力。大多数VM病例发生于结节性多动脉炎（PAN）、抗中性粒细胞胞浆抗体（ANCA）相关性血管炎或类风湿性血管炎的背景下，或表现为单器官血管炎。对于VM的肌肉炎症，目前了解甚少，大多数研究主要报道了骨骼肌组织显微分析下可见的血管炎性改变。然而，迄今尚未进行详细的表征或深入分析。本研究在ANCA检测阴性的背景下，对12例患者的临床病理表型进行了研究，并分析了36例患者的基因表达谱。ANCA阴性的VM通常表现为累及下肢的肌痛，伴有皮肤表现、全身症状及显著的系统性炎症。半数患者（6/12，50.0%）符合“典型PAN”的分类标准。多数病例中血清肌酸激酶（CK）活性正常（10/12，83.3%）。组织病理学在9/12（75.0%）例中证实存在骨骼肌血管炎。具体而言，ANCA阴性的VM主要累及小动脉，且与筋膜表层小血管的受累密切相关（9/10，90.0%），这一特征被称为“血管炎性筋膜炎”（VF）。部分病例中可见坏死性血管炎的迹象（3/9，33.3%）。轻度肌内膜纤维化及肌纤维坏死提示疾病起病较急，分别可能解释血清CK活性正常或轻度升高的情况。此外，在所有分析的肌肉活检标本中均观察到非特异性肌病性改变，如毛细血管壁增厚及肌纤维大小不均。免疫组织化学研究显示，大多数病例（10/11，90.9%）存在主要组织相容性复合体I类（MHC-I）在肌膜周围的灶周上调。通过对36例ANCA阴性VM患者的肌肉活检进行RNA测序，并与37例健康对照和649例其他炎性肌病样本比较，结果发现ANCA阴性VM以干扰素-γ驱动的免疫反应为主特征，伴有包括肿瘤坏死因子相关基因在内的广泛细胞因子激活，以及血管生成和内皮相关转录本的选择性上调。我们的组织形态学分析强调了VF的一种独特组织病理学模式，是ANCA阴性血管炎肌肉受累的特征性表现。此外，我们提供了一个特异性分子特征，为ANCA阴性VM的发病机制与治疗提供了新的见解。

### 第二部分 AI 大师评价

本研究系统阐述了ANCA阴性血管炎性肌病的临床和分子病理特征，提出“血管炎性筋膜炎”这一独特亚型。作者结合组织病理学和RNA测序分析，揭示该疾病以干扰素-γ驱动的炎症反应为核心，并伴有血管生成及内皮相关基因上调。这项研究为理解该类肌病的发病机制提供了重要线索，亦为未来靶向干扰素通路的治疗策略奠定了基础。局限性在于样本量有限，仍需更大规模研究验证其分子特征的普适性。

---

## 2. 人工智能驱动的荧光探针发现加速研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41441857)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41441857
**DOI：** 10.1002/advs.202515604

### 第一部分 原文与翻译

**英文原标题：** AI-Driven Acceleration of Fluorescence Probe Discovery.

> **英文摘要：**
> Fluorescence imaging probes are indispensable tools for clinical navigation and preclinical research. However, the discovery of target-specific probes is hampered by the scarcity of targetable fluorophore scaffolds, making the development process slow, costly, and heavily reliant on trial-and-error design. Here, we present a hybrid strategy that integrates AI with bioassays to accelerate the development of target-specific fluorescent probes. We developed an AI model (PROBY) based on over one million molecule entries from nine datasets, capable of identifying fluorescent molecules and predicting seven key photophysical properties. Applying PROBY to a library of 26,416 target-validated molecules, we identified thousands of candidates with both target affinity and favorable optical characteristics. Focusing on three clinically relevant targets (tau, BCL-2, and TDP-43), we validated AI-identified candidates and discovered PE859, obatoclax, and B3, which supported applications in spectral analysis, drug screening, pathological labeling, cell imaging, and ex vivo tumor imaging. Guided by PROBY, we chemically modify PE859, yielding two optimized derivatives (859-1 and 859-2). With improved photophysical properties, 859-2 enabled in vivo two-photon imaging of tau pathology in transgenic mice. This hybrid AI-bioassay strategy substantially broadens the accessible scaffold landscape for designing target-specific fluorescence probes and provides a scalable, efficient, and cost-effective framework for next-generation probe discovery.

> **中文摘要：**
> 荧光成像探针是临床导航和临床前研究中不可或缺的工具。然而，靶向特异性探针的发现受到可靶向荧光团骨架稀缺的限制，使得开发过程缓慢、成本高昂，并且高度依赖试错式设计。在本研究中，我们提出了一种将人工智能与生物检测相结合的混合策略，以加速靶向特异性荧光探针的开发。我们基于来自九个数据集的逾一百万个分子条目构建了一个AI模型（PROBY），该模型能够识别荧光分子并预测七项关键的光物理性质。将PROBY应用于一个包含26,416个靶点验证分子的库后，我们鉴定出数千个同时具有靶点亲和性和优良光学特性的候选分子。针对三个临床相关靶点（tau、BCL-2和TDP-43），我们验证了AI筛选出的候选分子，并发现了PE859、obatoclax和B3，这些分子可用于光谱分析、药物筛选、病理标记、细胞成像以及离体肿瘤成像等。根据PROBY的指导，我们对PE859进行了化学改造，获得了两个优化衍生物（859-1和859-2）。其中，具有改进光物理特性的859-2实现了在转基因小鼠体内对tau病理的双光子成像。这一AI-生物检测混合策略显著拓宽了可用于设计靶向特异性荧光探针的骨架范围，并为下一代探针发现提供了一种可扩展、高效且具成本效益的框架。

### 第二部分 AI 大师评价

该研究以AI驱动的策略显著加速了靶向荧光探针的设计与发现，体现出人工智能在化学生物学领域的创新应用。作者构建的PROBY模型能同时识别荧光分子及预测关键光物理特性，并通过生物实验验证实现了候选探针的有效筛选。研究进一步优化了代表性分子，并成功实现了神经变性相关tau蛋白的体内成像，展示了AI指导下的分子优化潜力。该方法兼具可扩展性与实用性，但在模型泛化与实验验证深度上仍有持续完善的空间。

---

## 3. CpG岛中核小体缠绕能量及表观遗传碱基修饰的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41439494)
**期刊：** eLife
**PMID：** 41439494
**DOI：** 10.7554/eLife.98468

### 第一部分 原文与翻译

**英文原标题：** Nucleosome wrapping energy in CpG islands and the role of epigenetic base modifications.

> **英文摘要：**
> The majority of vertebrate promoters have a distinct DNA composition, known as a CpG island. Cytosine methylation in promoter CpG islands is associated with a substantial reduction of transcription initiation. We hypothesise that both atypical sequence composition and epigenetic base modifications may affect the mechanical properties of DNA in CpG islands, influencing the ability of proteins to bind and initiate transcription. In this work, we model two scalar measures of the sequence-dependent propensity of DNA to wrap into nucleosomes: the energy of DNA required to assume a particular nucleosomal configuration and a measure related to the probability of linear DNA spontaneously reaching the nucleosomal configuration. We find that CpG density and modification state can alter DNA mechanics by creating states more or less compatible with nucleosome formation.

> **中文摘要：**
> 大多数脊椎动物的启动子具有一种独特的DNA组成，称为CpG岛。启动子CpG岛中胞嘧啶甲基化与转录起始的显著降低相关。我们假设，异常的序列组成与表观遗传碱基修饰均可能影响CpG岛中DNA的力学特性，从而影响蛋白质结合及启动转录的能力。在本研究中，我们建立了两个用于描述DNA序列依赖性缠绕入核小体倾向的标量指标：其一是DNA形成特定核小体构象所需的能量，其二是线性DNA自发达到核小体构象的概率相关指标。我们的结果表明，CpG密度及其修饰状态能够通过改变DNA的力学特性，产生更适合或较不适合核小体形成的状态。

### 第二部分 AI 大师评价

本研究聚焦于CpG岛的DNA力学特性及表观遗传修饰的作用机制。作者通过理论建模定量分析DNA缠绕入核小体的能量与自发形成可能性，揭示了序列组成和甲基化状态对核小体组装的调控影响。该工作在将DNA序列特性与物理能量学相结合方面具有创新意义，为理解启动子表观遗传调控提供了新思路。然而，模型仍需结合实验验证以支持其生物学相关性。

---

## 4. 使用[11C]AZ14193391在非人灵长类、健康志愿者及胶质母细胞瘤患者中进行PARP1结合的亚型选择性PET成像研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41437644)
**期刊：** Neuro-oncology
**PMID：** 41437644
**DOI：** 10.1093/neuonc/noaf290

### 第一部分 原文与翻译

**英文原标题：** Subtype selective PET imaging of PARP1 binding in non-human primates, healthy volunteers and patients with glioblastoma using [11C]AZ14193391.

> **英文摘要：**
> BACKGROUND: Poly ADP-ribose polymerase-1 (PARP1) is a key enzyme in DNA damage repair and an established target for cancer drug treatment. Although the emergence of non-invasive imaging of PARP using PET has opened new opportunities in cancer diagnosis and drug development, subtype selective imaging of the enzyme, and particularly in brain, remains an unmet need.
> 
> METHODS: The potent and selective novel PARP inhibitor AZ14193391 was labeled with carbon-11 and evaluated as a candidate PET radioligand for PARP1 through a series of translational in vitro and in vivo molecular imaging studies. These studies encompassed PET in non-human primates, healthy volunteers and patients with glioblastoma.
> 
> RESULTS: Robust radioligand binding to PARP1 was observed in the healthy non-human primate and human brain both in vitro and in vivo. Elevated tumor binding with high contrast was also demonstrated in patients with glioblastoma.
> 
> CONCLUSIONS: The novel PET radioligand, [11C]AZ14193391 enables subtype selective imaging of PARP1 binding. Its ability to image this protein in the human brain paves the way for accelerated research, diagnosis and drug development in neuro-oncology.

> **中文摘要：**
> 背景：多聚腺苷二磷酸核糖聚合酶-1（PARP1）是DNA损伤修复的关键酶，也是已确立的癌症药物治疗靶点。尽管利用PET进行PARP的非侵入性成像已为癌症诊断和药物研发开辟了新的可能性，但针对该酶的亚型选择性成像，尤其是在脑内，仍是一项未满足的需求。
> 
> 方法：将具有高效力和高选择性的创新性PARP抑制剂AZ14193391标记碳-11，并通过一系列体外和体内的转化分子影像研究评估其作为PARP1候选PET放射性配体的可行性。这些研究包括在非人灵长类、健康志愿者以及胶质母细胞瘤患者中进行的PET成像。
> 
> 结果：在健康非人灵长类及人脑中，无论体外还是体内，均观察到与PARP1的强结合。此外，在胶质母细胞瘤患者中也证实了肿瘤部位具有高对比度的放射性配体结合。
> 
> 结论：这一新型PET放射性配体[11C]AZ14193391能够实现PARP1结合的亚型选择性成像。其在人体脑内对该蛋白进行成像的能力，为神经肿瘤学领域加速研究、诊断与药物开发奠定了基础。

### 第二部分 AI 大师评价

本研究旨在开发并验证一种新型PET放射性配体[11C]AZ14193391，以实现PARP1靶点的亚型选择性影像。研究采用系统的体外与体内实验，覆盖非人灵长类、健康人和胶质母细胞瘤患者，验证了其在脑组织和肿瘤中的特异性结合。结果显示该化合物在脑内具有良好的靶向性和成像对比，为神经肿瘤学中非侵入性检测PARP1提供了新的工具。创新之处在于其首次验证了具亚型选择性的脑内PARP1成像潜力，但仍需进一步评估其临床应用的可行性与放射安全性。

---

## 5. USP43 通过稳定 E2F1 调控胆固醇稳态，促进膀胱癌对吉西他滨的耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41437393)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41437393
**DOI：** 10.1186/s13046-025-03621-2

### 第一部分 原文与翻译

**英文原标题：** USP43 promotes gemcitabine resistance by regulating cholesterol homeostasis through E2F1 stabilization in bladder cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本研究题目指出 USP43 可通过稳定 E2F1，从而调控胆固醇稳态，进而促进膀胱癌对吉西他滨的耐药性，提示其在化疗耐药机制中的关键作用。研究可能结合分子生物学与代谢调控的视角，为克服膀胱癌化疗耐药提供新靶点。其创新性在于揭示 USP43–E2F1–胆固醇代谢轴在肿瘤药物耐受中的作用。然而，由于尚无摘要和实验细节，具体机制验证和临床相关性仍需进一步探索。

---

## 6. 靶向 CD47-HCK-LGALS9 轴可破坏早期子宫内膜癌中增殖与免疫抑制的耦合机制。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41437376)
**期刊：** Molecular cancer
**PMID：** 41437376
**DOI：** 10.1186/s12943-025-02534-0

### 第一部分 原文与翻译

**英文原标题：** Targeting the CD47-HCK-LGALS9 axis disrupts proliferation-immunosuppression coupling in early-stage endometrial cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于早期子宫内膜癌中 CD47-HCK-LGALS9 信号轴的生物学功能，揭示了该通路在肿瘤细胞增殖与免疫抑制之间的相互联系。通过靶向该轴，研究团队可能发现干预肿瘤免疫逃逸的新策略。这一研究思路具有较强的创新性，有望为精准免疫治疗提供新靶点。由于暂无具体摘要，实验细节及验证手段需进一步确认。

---

## 7. NeoGuider：基于高级特征工程的新表位预测方法

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41437280)
**期刊：** Genome medicine
**PMID：** 41437280
**DOI：** 10.1186/s13073-025-01592-9

### 第一部分 原文与翻译

**英文原标题：** NeoGuider: neoepitope prediction using advanced feature engineering.

> **英文摘要：**
> The design of neoepitope-based cancer immunotherapy requires predicting the immunogenicity of each patient-specific neoepitope candidate. We designed NeoGuider, a machine-learning model to address nonlinearity and class imbalance in such prediction. Central to NeoGuider is a supervised feature-transformation approach, which estimates odds using our custom kernel density estimation followed by centered isotonic regression. We implemented NeoGuider as a bioinformatics pipeline, which detects neoepitope candidates from sequencing data and prioritizes such candidates by predicted immunogenicity. Benchmarking on 7 cohorts, 113 patients, and 635 immunogenic candidates showed that NeoGuider outperformed existing methods in neoepitope prediction. NeoGuider is open-source at https://github.com/XuegongLab/neoguider.

> **中文摘要：**
> 基于新表位的癌症免疫治疗设计需要预测每个患者特异性新表位候选物的免疫原性。我们设计了 NeoGuider，这是一种机器学习模型，用于解决此类预测中的非线性和类别不平衡问题。NeoGuider 的核心是一个监督式特征转换方法，该方法先采用我们自定义的核密度估计来估算比率，然后进行中心等距回归。我们将 NeoGuider 实现为一个生物信息学分析流程，可从测序数据中检测新表位候选物，并根据预测免疫原性对这些候选物进行优先排序。在7个队列、113名患者和635个免疫原性候选物的基准测试中，NeoGuider 在新表位预测中表现优于现有方法。NeoGuider 已作为开源工具发布于 https://github.com/XuegongLab/neoguider。

### 第二部分 AI 大师评价

该研究旨在优化新表位预测以提升癌症个体化免疫治疗的设计效率。作者提出的 NeoGuider 模型通过监督式特征转换、核密度估计和中心等距回归的结合，有效解决了非线性与类不平衡问题。其实验结果表明，该方法在多队列数据上优于现有模型，展现出较强的泛化和预测能力。其开源实现增强了方法的可复现性，但后续仍需在更多异质性数据集上验证其临床适用性。

---

## 8. 过渡型循环肿瘤细胞可预测胰腺导管腺癌切除后的系统性复发，并支持化疗风险分层：CLUSTER 试验的长期结局研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41437172)
**期刊：** Annals of surgery
**PMID：** 41437172
**DOI：** 10.1097/SLA.0000000000006998

### 第一部分 原文与翻译

**英文原标题：** Transitional Type Circulating Tumor Cells Predict Systemic Recurrence and Support Risk Stratification for Chemotherapy After Resection of Pancreatic Ductal Adenocarcinoma: Long-term Outcomes of the CLUSTER Trial.

> **英文摘要：**
> AIM: To evaluate whether transitional circulating tumor cells (trCTCs) predict systemic recurrence of pancreatic ductal adenocarcinoma (PDAC) and assess their potential role in risk stratification for systemic treatment.
> 
> BACKGROUND: The high metastatic potential of PDAC is believed to be associated with early dissemination after cancer cell reprogramming via an epithelial-to-mesenchymal transition. These cells are detectable in circulation as trCTCs and could serve as valuable biomarker capturing systemic disease involvement.
> 
> METHODS: The prospective CLUSTER trial enrolled patients scheduled for PDAC resection (2016-2018). Pre- and postoperative CTCs were isolated with the Isolation-by-SizE-of-Tumor-Cells device and characterized by immunofluorescence. Cox regression with spline terms assessed associations between preoperative biomarkers and systemic recurrence, while multivariable subgroup analyses with interaction tests evaluated overall survival (OS) stratified by adjuvant chemotherapy.
> 
> RESULTS: In preoperative samples, trCTCs were detected in 82 (67%) of 123 patients with a median number of two cells per ml (IQR 1-3). A linear association between preoperative trCTC counts and systemic recurrence (χ²=13.2, P=0.004) was observed, but no relevant correlation with CA19-9 levels was found (Pearson correlation=0.05, 95% CI:-0.13-0.23). Furthermore, trCTC-positivity after resection predicts recurrence and is associated with prolonged OS associated with adjuvant therapy (HR 0.21, 95%CI: 0.09-0.49) after adjustment for tumor stage and neoadjuvant chemotherapy.
> 
> CONCLUSIONS: Preoperatively, higher trCTC counts are associated with increased risk of systemic recurrence, while postoperative presence reflects minimal residual disease. Integrating trCTC assessment alongside currently used biomarkers into the clinical pathway for patients with PDAC could enhance risk stratification and support more personalized treatment decisions.

> **中文摘要：**
> 研究目的：评估过渡型循环肿瘤细胞（transitional circulating tumor cells，trCTCs）是否可预测胰腺导管腺癌（pancreatic ductal adenocarcinoma，PDAC）的系统性复发，并探讨其在系统治疗风险分层中的潜在作用。
> 
> 研究背景：PDAC 的高转移潜能被认为与肿瘤细胞经由上皮-间质转化（epithelial-to-mesenchymal transition）后的早期播散有关。这些经重编程的肿瘤细胞可在外周血中检测为 trCTCs，可能作为反映全身疾病累及的有价值生物标志物。
> 
> 研究方法：前瞻性 CLUSTER 试验纳入 2016–2018 年计划接受 PDAC 切除的患者。术前和术后样本中的循环肿瘤细胞（CTCs）通过基于肿瘤细胞尺寸分离的装置（Isolation-by-SizE-of-Tumor-Cells）进行分离，并采用免疫荧光方法进行表型鉴定。采用包含样条项的 Cox 回归模型分析术前生物标志物与系统性复发之间的关联，同时通过多变量亚组分析和交互作用检验评估按辅助化疗分层的总体生存（OS）。
> 
> 研究结果：在术前样本中，123 名患者中有 82 名（67%）检测到 trCTCs，中位数为 2 个细胞/mL（IQR 1–3）。术前 trCTCs 数量与系统性复发呈线性相关（χ²=13.2，P=0.004），但与 CA19-9 水平无相关性（皮尔森相关系数=0.05，95% CI：-0.13–0.23）。此外，术后 trCTC 阳性可预测复发，并在调整肿瘤分期及新辅助化疗后，与接受辅助治疗的患者较长的总体生存显著相关（HR 0.21，95% CI：0.09–0.49）。
> 
> 研究结论：术前 trCTC 水平较高与系统性复发风险升高相关，而术后 trCTC 的存在提示最小残留病灶。将 trCTC 评估与目前使用的生物标志物相结合，纳入 PDAC 患者的临床管理流程中，可强化风险分层并支持更加个体化的治疗决策。

### 第二部分 AI 大师评价

该研究通过 CLUSTER 前瞻性临床试验验证了过渡型循环肿瘤细胞（trCTCs）在胰腺导管腺癌中的预测价值。结果显示，术前 trCTC 数量与系统复发呈显著线性相关，术后 trCTC 阳性提示残留疾病，并可在辅助化疗下带来更佳生存。该研究为将 CTC 亚型纳入 PDAC 风险评估提供了重要证据，具有较强的临床转化潜力。其局限性在于样本量有限及生物标志物检测的技术依赖，仍需进一步外部验证。

---

## 9. 乳腺癌中的组蛋白赖氨酸去甲基化酶：分子机制、生物学功能及治疗干预

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41437062)
**期刊：** Molecular cancer
**PMID：** 41437062
**DOI：** 10.1186/s12943-025-02512-6

### 第一部分 原文与翻译

**英文原标题：** Histone lysine demethylases in breast cancer: molecular mechanisms, biological functions, and therapeutic intervention.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该研究聚焦于乳腺癌中组蛋白赖氨酸去甲基化酶的作用，探讨其在分子机制、信号调控及潜在治疗靶点方面的重要性。尽管未提供具体摘要，但根据题目推测，该文可能综述了去甲基化酶在肿瘤表观遗传调控中的功能网络，并评估其作为药物靶点的可行性。其创新之处在于系统化整合分子机制与治疗干预视角，为乳腺癌精确治疗提供新思路。然而，实际应用仍需更多临床与机制验证。

---

## 10. NSUN2介导的异常5-甲基胞嘧啶甲基化调控与自噬相关的铁死亡过程，促进口腔鳞状细胞癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436732)
**期刊：** Cell death & disease
**PMID：** 41436732
**DOI：** 10.1038/s41419-025-08174-y

### 第一部分 原文与翻译

**英文原标题：** NSUN2 mediated-aberrant 5-methylcytosine methylation regulates autophagy-related ferroptosis in oral squamous cell carcinoma progression.

> **英文摘要：**
> Oral squamous cell carcinoma (OSCC) is a common malignant tumor with high metastasis rates and poor prognosis. This study investigated the role of NOP2/Sun RNA methyltransferase family member 2 (NSUN2), a key 5-methylcytosine (m5C) methyltransferase, and m5C methylation in the progression of OSCC, particularly in relation to ferroptosis resistance. NSUN2 is significantly overexpressed in OSCC tissues and cell lines and its high expression correlates with poor prognosis and aggressive tumor characteristics. Knockdown of NSUN2 in ferroptosis-resistant OSCC cells resulted in increased sensitivity to ferroptosis. Conversely, NSUN2 overexpression conferred ferroptosis resistance, reducing iron accumulation and restoring GPX4 expression even under erastin treatment. Mechanistically, NSUN2 mediates m⁵C modification of sequestosome 1 (SQSTM1)/P62 mRNA, and the m5C reader protein Y-box binding protein 1 (YBX1) enhances SQSTM1/P62 mRNA stability. This regulation suppresses autophagy and thereby inhibits autophagy-dependent ferroptosis in OSCC. In vivo xenograft models confirmed that NSUN2 knockdown significantly inhibited tumorigenicity. Notably, treatment with an autophagy inhibitor (3-MA) or a ferroptosis inhibitor (Fer-1) partially restored tumor growth in NSUN2-knockdown cells, validating the critical role of autophagy and ferroptosis in NSUN2-mediated OSCC progression. These findings identify the NSUN2-YBX1-SQSTM1/P62 axis as a key regulator of autophagy-dependent ferroptosis in OSCC, highlighting NSUN2 as a promising epitranscriptomic target to enhance ferroptosis induction for OSCC therapy.

> **中文摘要：**
> 口腔鳞状细胞癌（OSCC）是一种常见的恶性肿瘤，具有高转移率和预后不良的特点。本研究探讨了NOP2/Sun RNA甲基转移酶家族成员2（NSUN2），一种关键的5-甲基胞嘧啶（m5C）甲基转移酶，以及m5C甲基化在OSCC进展中的作用，特别是其与铁死亡耐受性的关系。研究发现，NSUN2在OSCC组织及细胞系中显著高表达，其高表达与不良预后及侵袭性肿瘤特征相关。在铁死亡耐受的OSCC细胞中敲低NSUN2可增强其对铁死亡的敏感性。相反，过表达NSUN2可赋予细胞铁死亡耐受性，即使在erastin处理下，仍能减少铁积累并恢复GPX4的表达。在机制上，NSUN2介导了对sequestosome 1 (SQSTM1)/P62 mRNA的m⁵C修饰，而m5C识读蛋白Y-box结合蛋白1（YBX1）能够增强SQSTM1/P62 mRNA的稳定性。该调控机制抑制了自噬，从而阻断了OSCC中的自噬依赖性铁死亡。在体内异种移植模型中，敲低NSUN2能显著抑制肿瘤形成。值得注意的是，使用自噬抑制剂（3-MA）或铁死亡抑制剂（Fer-1）处理可部分恢复NSUN2敲低细胞的肿瘤生长，验证了自噬与铁死亡在NSUN2介导的OSCC进展中的关键作用。这些发现揭示了NSUN2-YBX1-SQSTM1/P62轴是OSCC中自噬依赖性铁死亡的重要调控通路，并突出了NSUN2作为促进铁死亡诱导、用于OSCC治疗的有前景的表观转录组学靶点。

### 第二部分 AI 大师评价

该研究系统阐明了NSUN2介导的m5C甲基化在口腔鳞状细胞癌中通过调控自噬和铁死亡过程影响肿瘤进展的机制。作者结合体内外实验发现，NSUN2通过YBX1增强SQSTM1/P62 mRNA稳定性，从而抑制自噬依赖性铁死亡，并促进肿瘤生长。研究创新性地揭示了表观转录组修饰与铁死亡间的联系，为开发NSUN2相关的铁死亡靶向治疗提供新方向。其局限性在于尚需临床样本及患者预后数据进一步验证通路的实用价值。

---

## 11. Ⅲ期非小细胞肺癌诱导化学-免疫治疗联合同步放化疗及免疫维持治疗（APOLO研究）：一项Ⅱ期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436730)
**期刊：** Nature communications
**PMID：** 41436730
**DOI：** 10.1038/s41467-025-66097-w

### 第一部分 原文与翻译

**英文原标题：** Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial.

> **英文摘要：**
> Unresectable stage III NSCLC standard treatment is chemo-radiotherapy (CT-RT) followed by immunotherapy (IO) with durvalumab. We investigated adding an induction phase with chemo-immunotherapy (ChIO). APOLO was a multicentre, single-arm, phase 2 trial (NCT04776447). Non-resectable stage IIIA-IIIC NSCLC patients received induction ChIO (atezolizumab + carboplatin + paclitaxel, for 3 cycles), followed by concurrent CT-RT (3 cycles), and IO maintenance (atezolizumab for 16 cycles). Primary objective was 12-month progression-free survival (PFS). Secondary endpoints included 12- and 24-month overall survival (OS), ORR, first-site failure pattern, and safety. Exploratory endpoints included PD-L1, TMB, and ctDNA. 38 patients were enrolled. Median follow-up was 29.6 months (data cutoff, February 2024). PFS was 68.4% (95% CI, 51.1-80.7) at 12 months (statistically significant compared to null hypothesis of 55%) and 50.0% at 24 months; OS was 86.8% and 60.5%, respectively. After induction, 18 (47.4%) had partial response, 14 (36.8%) stable disease, and 5 (13.2%) progressive disease. Overall, 18 patients had disease progression: 8 local (44.4%) and 10 distant (55.6%). Grade ≥3 TRAEs occurred in 11 (28.9%) during induction, 10 (26.3%) during CT-RT, and 2 (5.3%) during maintenance. ChIO induction before CT-RT and IO maintenance showed activity and safety, warranting confirmation in larger studies.

> **中文摘要：**
> 在不可切除的Ⅲ期非小细胞肺癌（NSCLC）中，标准治疗为同步放化疗（CT-RT），随后进行使用度伐利尤单抗的免疫治疗（IO）。我们探讨了在治疗方案中增加诱导性化学-免疫治疗（ChIO）阶段的可行性。APOLO研究是一项多中心、单臂、Ⅱ期临床试验（NCT04776447）。不可切除的ⅢA至ⅢC期NSCLC患者接受诱导性ChIO治疗（阿替利珠单抗 + 卡铂 + 紫杉醇，3个周期），随后接受同步CT-RT（3个周期），并进行免疫维持治疗（阿替利珠单抗，共16个周期）。主要研究终点为12个月无进展生存期（PFS）。次要终点包括12个月和24个月总生存率（OS）、客观缓解率（ORR）、首发进展部位及安全性。探索性终点包括PD-L1表达、肿瘤突变负荷（TMB）及循环肿瘤DNA（ctDNA）。共入组38例患者。中位随访时间为29.6个月（数据截止至2024年2月）。12个月PFS为68.4%（95% CI, 51.1–80.7），相较于55%的零假设具有统计学显著差异，24个月PFS为50.0%；OS分别为86.8%与60.5%。诱导治疗后，18例（47.4%）出现部分缓解，14例（36.8%）为疾病稳定，5例（13.2%）为疾病进展。总体共有18例发生疾病进展，其中8例（44.4%）为局部复发，10例（55.6%）为远处转移。≥3级治疗相关不良事件（TRAE）在诱导期出现11例（28.9%）、CT-RT期间10例（26.3%）、维持期2例（5.3%）。在CT-RT及免疫维持治疗前进行ChIO诱导显示出一定的活性与安全性，需在更大规模研究中进一步验证。

### 第二部分 AI 大师评价

本研究评估了在标准同步放化疗和免疫维持治疗前增加诱导性化学-免疫治疗的可行性与临床效果。Ⅱ期单臂试验结果表明，该策略在Ⅲ期不可切除的NSCLC患者中可取得较高的12个月无进展生存率和总体生存率，同时安全性可接受。研究创新性在于探索三阶段序贯策略对局部晚期肺癌的增效作用。尽管样本量较小且无对照组，但结果为优化放化疗联合免疫治疗的时序提供了重要依据。

---

## 12. 癌细胞端粒维持机制的大规模药物敏感性、基因依赖性及蛋白质组学-基因组学综合分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436729)
**期刊：** Nature communications
**PMID：** 41436729
**DOI：** 10.1038/s41467-025-67190-w

### 第一部分 原文与翻译

**英文原标题：** Large-scale drug sensitivity, gene dependency, and proteogenomic analyses of telomere maintenance mechanisms in cancer cells.

> **英文摘要：**
> Replicative immortality is a hallmark of cancer, driven by the activation of telomere maintenance mechanisms, that is yet to be therapeutically exploited. To expedite discoveries that will enable the development of therapeutics that target telomere maintenance mechanisms, this study provides a resource of telomere biology metrics for a pan-cancer panel of 976 cell lines. We generate proteomic data from data-independent-acquisition mass spectrometry for most of these cell lines and integrate pre-existing multi-omic, drug sensitivity, and molecular dependency data from CRISPR/Cas9 knock-out screens. The data illustrate a broad range and heterogeneity in telomere biology, including states that diverge from the binary model of telomere maintenance activation involving either telomerase or the Alternative Lengthening of Telomeres mechanism. Using the telomere biology metrics and multi-omic data, we derive proteomic and transcriptomic predictors of Alternative Lengthening of Telomeres and telomerase activity levels. Our investigations also reveal molecular vulnerabilities associated with the Alternative Lengthening of Telomeres mechanism and drug sensitivity correlating with telomerase activity levels. These findings illustrate opportunities for leveraging this resource to realize the potential for telomere biology-directed cancer therapeutics and companion diagnostics.

> **中文摘要：**
> 复制性永生是癌症的标志特征，由端粒维持机制的激活驱动，但这一过程尚未被治疗性地加以利用。为加速支持靶向端粒维持机制药物开发的发现，本研究为976株跨癌种细胞系提供了端粒生物学指标资源。研究者利用数据非依赖采集质谱技术为其中大多数细胞系生成了蛋白质组学数据，并整合了既有的多组学、药物敏感性及来自CRISPR/Cas9敲除筛选的分子依赖性数据。这些数据揭示了端粒生物学的广泛差异与异质性，包括超出传统二分模型（即端粒酶或替代性端粒延长机制）的多样状态。基于端粒生物学指标及多组学数据，研究推导出可预测替代性端粒延长机制活性及端粒酶活性水平的蛋白质组学与转录组学特征。此外，研究还发现与替代性端粒延长机制相关的分子脆弱性，以及与端粒酶活性水平相关的药物敏感性。这些发现揭示了利用该资源促进端粒生物学导向的抗癌治疗与伴随诊断开发的潜力。

### 第二部分 AI 大师评价

该研究系统性地构建了涵盖976株癌细胞系的端粒维持机制多组学数据库，整合蛋白质组、转录组、药物敏感性及CRISPR依赖性信息，为端粒生物学研究提供了前所未有的广度。其创新之处在于突破传统仅关注端粒酶或替代性端粒延长的二元模型，揭示了更复杂的端粒动态及潜在分子脆弱点。研究结果不仅促进端粒调控机制的理解，也为靶向端粒过程的抗癌药物与伴随诊断提供了理论依据和数据支撑。潜在局限在于细胞系模型对临床肿瘤环境的代表性仍需进一步验证。

---

## 13. 同时靶向 KRAS 与 CDK4 协同诱导胰腺癌细胞的持久性生长停滞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436723)
**期刊：** Cell death & disease
**PMID：** 41436723
**DOI：** 10.1038/s41419-025-08362-w

### 第一部分 原文与翻译

**英文原标题：** Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells.

> **英文摘要：**
> Mutant Ras oncoproteins, particularly KRAS, are among the most prevalent drivers of cancer. Small-molecule KRAS inhibitors have emerged as promising cancer therapeutics, yet resistance development remains a major hurdle. To overcome this challenge, we explored rational combination strategies aimed at enhancing therapeutic efficacy and durability. We show that the KRAS-G12C inhibitor Sotorasib synergizes with the CDK4/6 inhibitor Palbociclib to eliminate pancreatic ductal adenocarcinoma (PDAC) cells and organoids harboring KRAS-G12C mutations. This synergy was especially pronounced following drug washout, indicating a durable cellular response. Similar synergistic effects were observed in non-small-cell lung cancer (NSCLC) cells. Additionally, the KRAS-G12D inhibitor MRTX1133 cooperated with Palbociclib to suppress growth of KRAS-G12D-mutant PDAC cells. Mechanistically, the combinations induced sustained cell cycle arrest, marked by reduced RB phosphorylation, decreased E2F1 expression, and increased levels of CDKN1B/p27. Deletion of CDKN1B largely reversed the growth-inhibitory effect, highlighting its essential role in mediating the observed synergy. In an orthotopic, immunocompetent mouse model of PDAC, MRTX1133 significantly reduced tumor growth and extended survival; however, despite its ability to suppress RB phosphorylation, Palbociclib failed to enhance these effects. Single-cell RNA sequencing suggested that Palbociclib treatment induces tumor vascularization, perhaps contributing to the lack of drug synergy observed in vivo. In summary, our findings demonstrate the therapeutic potential of enhancing cell cycle restriction point activation in KRAS inhibitor-based therapies, while emphasizing the importance of placing combination therapies into a suitable context.

> **中文摘要：**
> 突变型 Ras 癌蛋白，尤其是 KRAS，是最常见的癌症驱动因子之一。小分子 KRAS 抑制剂已成为一种有前景的抗癌疗法，但耐药性的产生仍是主要障碍。为应对这一挑战，我们探索了旨在提高治疗效力和持久性的合理联合策略。研究表明，KRAS-G12C 抑制剂 Sotorasib 与 CDK4/6 抑制剂 Palbociclib 协同作用，可清除携带 KRAS-G12C 突变的胰腺导管腺癌（PDAC）细胞及类器官。这种协同效应在停药后尤为明显，提示产生了持久的细胞反应。类似的协同效应也在非小细胞肺癌（NSCLC）细胞中观察到。此外，KRAS-G12D 抑制剂 MRTX1133 与 Palbociclib 协同抑制了携带 KRAS-G12D 突变的 PDAC 细胞的生长。从机制上看，这些联合疗法诱导了持续的细胞周期停滞，其特征包括 RB 磷酸化降低、E2F1 表达减少以及 CDKN1B/p27 水平升高。CDKN1B 的缺失几乎逆转了抑制生长的效应，突显了其在介导这种协同作用中的关键作用。在正位、免疫完整的 PDAC 小鼠模型中，MRTX1133 显著抑制肿瘤生长并延长生存期；然而，尽管 Palbociclib 能抑制 RB 磷酸化，但未能进一步增强这些作用。单细胞 RNA 测序分析提示，Palbociclib 处理可能促进肿瘤血管化，这或许解释了体内缺乏药物协同效应的原因。综上所述，我们的研究结果揭示了在 KRAS 抑制剂治疗中强化细胞周期限制点激活的治疗潜力，同时强调了将联合疗法置于合适生物学环境中的重要性。

### 第二部分 AI 大师评价

该研究聚焦于克服 KRAS 抑制剂疗效不持久的问题，提出联合 CDK4/6 抑制剂以增强治疗反应的策略。通过在 PDAC 和 NSCLC 模型中的多组实验，作者发现 KRAS 抑制剂与 Palbociclib 的协同可持续诱导细胞周期停滞，并揭示 CDKN1B 在这一效应中的关键作用。其创新之处在于揭示了耐药背后的细胞周期机制，并结合单细胞转录组数据探索体内失效的潜在原因。局限在于部分体内模型未能再现体外协同，提示肿瘤微环境需在后续研究中进一步考量。

---

## 14. 血栓性炎症与新诊断骨髓增殖性肿瘤患者的高血栓风险相关。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436639)
**期刊：** Leukemia
**PMID：** 41436639
**DOI：** 10.1038/s41375-025-02836-8

### 第一部分 原文与翻译

**英文原标题：** Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

> **英文摘要：**
> Thrombotic risk assessment is crucial in newly diagnosed essential thrombocythemia (ET) and polycythemia vera (PV) patients to guide cytoreductive therapy. We assessed whether thromboinflammation biomarkers would be good candidates to improve thrombosis risk stratification. We prospectively enrolled 394 newly diagnosed, cytoreductive therapy-naïve, ET and PV patients. We measured seven plasma biomarkers of neutrophil, monocyte, platelet, and endothelial activation, including NET markers, and evaluated their association with thrombosis risk scores at diagnosis. Multivariable analysis in the whole MPN cohort showed elevated calprotectin and tissue factor levels in high-risk versus low-risk patients using the conventional two-tiered score. This was also observed in ET patients only, but not in PV patients. Patients with a JAK2V617F allele burden >20% showed higher levels of three markers, including calprotectin, supporting its role in immunothrombosis. In PV patients, calprotectin correlated with the Venous Thrombosis Score (VETS), and five markers were elevated in those with prior venous thrombosis. Lastly, aspirin use was associated with lower H3Cit levels in patients with normal platelet counts, confirming its beneficial effect on NET formation. This is the largest study to date linking thromboinflammation markers to thrombotic risk in MPN patients and identifying potential biomarkers for future thrombosis risk scores.

> **中文摘要：**
> 对于新诊断的原发性血小板增多症（ET）和真性红细胞增多症（PV）患者，评估血栓风险对于指导细胞减灭治疗至关重要。我们评估了血栓性炎症生物标志物是否可作为改善血栓风险分层的候选指标。我们前瞻性纳入了394例新诊断、未接受细胞减灭治疗的ET和PV患者。我们测量了七种中性粒细胞、单核细胞、血小板及内皮细胞活化的血浆生物标志物（包括NET标志物），并评估了它们与诊断时血栓风险评分之间的关系。对整个MPN队列进行的多变量分析显示，使用传统的两级评分体系时，高风险患者的钙卫蛋白和组织因子水平均高于低风险患者。这一结果在ET患者中同样出现，但在PV患者中未见类似现象。JAK2V617F等位基因负荷超过20%的患者表现出三个标志物水平升高（包括钙卫蛋白），提示其在免疫性血栓形成中的作用。在PV患者中，钙卫蛋白与静脉血栓评分（VETS）相关，并且在既往有静脉血栓史的患者中有五种标志物升高。最后，在血小板计数正常的患者中，阿司匹林使用与较低的H3Cit水平相关，证实了其对NET形成的有益影响。这是迄今为止规模最大的研究，揭示了血栓性炎症标志物与MPN患者血栓风险之间的关联，并确定了未来血栓风险评分的潜在生物标志物。

### 第二部分 AI 大师评价

本研究旨在确认血栓性炎症标志物在骨髓增殖性肿瘤（MPN）患者血栓风险评估中的价值。研究设计为前瞻性、多指标检测，覆盖394例新诊断ET和PV患者，分析了多种免疫和凝血相关分子。结果显示钙卫蛋白及组织因子与高血栓风险显著相关，尤其在ET患者中表现突出，同时揭示JAK2V617F突变负荷与免疫血栓形成有关。研究验证了阿司匹林在调节NET形成中的保护作用。该研究样本量大、设计严谨，为MPN患者的个体化血栓风险评估提供了新思路，但仍需进一步机制研究及多中心验证。

---

## 15. 体内表达CD3/CD19双特异性T细胞连接器和α-PD-L1-Fc可实现针对CD19/PD-L1白血病的高效且持久免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436638)
**期刊：** Leukemia
**PMID：** 41436638
**DOI：** 10.1038/s41375-025-02832-y

### 第一部分 原文与翻译

**英文原标题：** In vivo expression of CD3/CD19 bispecific T-cell engager and α-PD-L1-Fc enables effective and durable immunotherapy for CD19/PD-L1 leukemia.

> **英文摘要：**
> Approximately 50% of B-ALL patients exhibit Blinatumomab (CD3/CD19 bispecific T-cell engager, BiTE) resistance, often with high tumor PD-L1 expression, limiting therapeutic efficacy. Combining Blinatumomab with PD-L1 blockade is promising but hindered by continuous infusion, short half-life, and high costs. We developed an economical, non-viral, single-dose intramuscular plasmid gene delivery for sustained (≥4 weeks) in vivo co-expression of CD3/CD19 BiTE and PD-L1 antibodies. This platform integrates T-cell-mediated cytotoxicity, immune checkpoint blockade, and antibody-dependent cytotoxicity. This strategy induced substantial leukemia cell regression, achieving an 80% complete remission (CR) rate in CD19⁺/PD-L1⁺ Nalm-6 xenografts and a 40% CR rate in the CD19 antigen-loss immune escape model. Anti-leukemic efficacy correlated with enhanced CD3⁺, CD8⁺ T-cell, CD3⁺CD56⁺ NKT-like cell expansion, and increased granzyme B/IFN-γ levels. Furthermore, in vivo-produced antibodies promoted B-ALL patient-derived CD3⁺ T-cell proliferation and CD19⁺ tumor cell clearance. This study presents a cost-effective, durable, and potent in vivo immunotherapy integrating T-cell engagement and PD-L1 blockade, offering a promising translational approach for B-ALL.

> **中文摘要：**
> 约50%的B-ALL患者表现出对Blinatumomab（CD3/CD19双特异性T细胞连接器，BiTE）的耐药性，往往伴有高水平的肿瘤PD-L1表达，从而限制了治疗效果。将Blinatumomab与PD-L1阻断联合应用具有潜力，但受到持续输注、短半衰期和高成本等因素的限制。我们开发了一种经济的、非病毒介导的、单次肌肉注射质粒基因递送系统，可在体内持续（≥4周）共表达CD3/CD19 BiTE和PD-L1抗体。该平台结合了T细胞介导的细胞毒性、免疫检查点阻断以及抗体依赖性细胞毒效应。这一策略诱导了显著的白血病细胞退缩，在CD19⁺/PD-L1⁺ Nalm-6异种移植模型中实现了80%的完全缓解（CR）率，在CD19抗原缺失的免疫逃逸模型中实现了40%的CR率。抗白血病疗效与CD3⁺、CD8⁺ T细胞、CD3⁺CD56⁺ NKT样细胞的扩增以及颗粒酶B/IFN-γ水平的升高密切相关。此外，体内产生的抗体促进了源自B-ALL患者的CD3⁺ T细胞增殖和CD19⁺肿瘤细胞清除。本研究提出了一种具有成本效益、持久且高效的体内免疫治疗策略，整合了T细胞招募与PD-L1阻断，为B-ALL提供了一种具有转化潜力的新型治疗途径。

### 第二部分 AI 大师评价

本研究旨在解决Blinatumomab在B-ALL治疗中因PD-L1高表达而导致的耐药问题。作者通过非病毒质粒递送系统实现CD3/CD19 BiTE与PD-L1抗体的体内持续共表达，显著改善了白血病模型的缓解率。结果显示该策略不仅增强了T细胞和NKT样细胞的免疫活性，还可促进患者源T细胞功能恢复。该方法具备高性价比和长效特征，具有较强的临床转化潜力，但仍需在安全性和人体应用可控性方面进一步验证。

---

## 16. Lipocalin-2 通过肿瘤与微环境的双向相互作用促进肺癌脑转移进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436606)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41436606
**DOI：** 10.1038/s41392-025-02514-2

### 第一部分 原文与翻译

**英文原标题：** Lipocalin-2 drives brain metastatic progression through reciprocal tumor-microenvironment interactions in lung cancer.

> **英文摘要：**
> Brain metastasis is a major contributor to mortality in patients with lung cancer. The unique microenvironment of the brain plays a critical role in the initiation and progression of brain metastases (BM), yet the molecular mechanisms underlying tumor-microenvironment interactions remain poorly understood. Here, we demonstrate that upregulation of lipocalin-2 (LCN2) in tumor cells promotes brain metastatic progression by orchestrating crosstalk among metastatic tumor cells, astrocytes, and macrophages. Brain metastatic tumor cells secrete LCN2, which binds to SLC22A17 on astrocytes, activating JAK2/STAT3 signaling and inducing astrocyte activation and chemokine secretion, thereby facilitating macrophage recruitment. In turn, macrophages secrete IL-1β, which further upregulates LCN2 expression in tumor cells. Prophylactic administration of the IL-1 receptor antagonist anakinra inhibits BM formation, whereas therapeutic administration alone is ineffective. However, treatment with the STAT3 inhibitor SH4-54, either alone or in combination with anakinra, significantly suppressed tumor growth in the BM. Furthermore, tumor-secreted LCN2 can bind to SLC22A17 on tumor cells, activating JAK2/STAT3 signaling and promoting VEGF-A expression and release, which enhances tumor neovascularization. Inhibition of this axis with SH4-54, bevacizumab, or their combination effectively reduces the tumor burden in BM-bearing mice. These findings underscore the central role of LCN2 in driving brain metastasis and highlight a potential therapeutic strategy for targeting brain metastatic lung cancer.

> **中文摘要：**
> 脑转移是导致肺癌患者死亡的主要原因之一。脑部独特的微环境在脑转移（BM）的发生和进展中起关键作用，但其肿瘤与微环境相互作用的分子机制尚不清楚。本文显示，肿瘤细胞中脂质运载蛋白-2（LCN2）的上调通过协调转移性肿瘤细胞、星形胶质细胞和巨噬细胞之间的串联信号，促进脑转移进展。脑转移性肿瘤细胞分泌 LCN2，该蛋白与星形胶质细胞上的 SLC22A17 结合，激活 JAK2/STAT3 信号通路，诱导星形胶质细胞活化并分泌趋化因子，从而促进巨噬细胞募集。随后，巨噬细胞分泌 IL-1β，进一步上调肿瘤细胞中 LCN2 的表达。预防性使用 IL-1 受体拮抗剂 anakinra 可抑制脑转移的形成，而单独治疗性使用则无明显效果。然而，使用 STAT3 抑制剂 SH4-54，无论单独还是与 anakinra 联合使用，都能显著抑制脑转移灶中的肿瘤生长。此外，肿瘤分泌的 LCN2 还可与肿瘤细胞表面的 SLC22A17 结合，激活 JAK2/STAT3 信号并促进 VEGF-A 的表达和释放，从而增强肿瘤新生血管形成。利用 SH4-54、贝伐珠单抗或二者联合抑制该轴，可有效降低脑转移小鼠的肿瘤负荷。这些发现强调了 LCN2 在推动脑转移中的核心作用，并为靶向脑转移性肺癌提供了潜在治疗策略。

### 第二部分 AI 大师评价

本研究揭示了 LCN2 在肺癌脑转移中发挥的关键促进作用，通过驱动肿瘤细胞、星形胶质细胞与巨噬细胞之间的信号互作，形成正向反馈环路，推动转移灶进展。作者利用分子机制实验与药物干预模型，阐明了 JAK2/STAT3 及 IL-1β 轴在脑转移微环境重塑中的作用。结果表明，联合使用 SH4-54 与 anakinra 能有效抑制脑转移生长，并指出靶向 LCN2 相关通路的潜在治疗意义。研究创新点在于揭示了 LCN2—SLC22A17 信号轴及其在脑转移新生血管化中的作用，但局限在于临床转化仍需更多验证。

---

## 17. 具有肿瘤穿透能力的抗MSLN嵌合抗原受体样自然杀伤细胞（uCAR-like NK）治疗实体瘤研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436559)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41436559
**DOI：** 10.1038/s41392-025-02524-0

### 第一部分 原文与翻译

**英文原标题：** Anti-MSLN chimeric antigen receptor-like NK cell therapy with tumor-penetrating capacity (uCAR-like NK) for solid tumors.

> **英文摘要：**
> Although natural killer (NK) cells are endowed with intrinsic cytotoxicity, their therapeutic application often faces limitations because of their lack of tumor-specific targeting ability and limited ability to infiltrate solid tumors. To overcome these limitations, we developed anti-mesothelin (MSLN) uCAR-like NK cells, which are designed to enhance both the targeting specificity and tumor infiltration capacity, thereby improving the antitumor efficacy of NK cell-based therapies. We constructed, purified, and validated a tetravalent bispecific cell engager (MSLN×CD16A) via the SpyTag/SpyCatcher system. Cytokine-induced memory-like NK cells, induced by IL-12, IL-15, and IL-18, were precomplexed with MSLN×CD16A to generate anti-MSLN CAR-like NK cells. To further enhance tumor penetration, the tumor-penetrating peptide uCendR was integrated into the system to construct anti-MSLN uCAR-like NK cells. In vitro, anti-MSLN CAR-like NK cells demonstrated selective cytotoxicity against MSLN-positive tumor cells through stable binding with MSLN×CD16A while sparing MSLN-negative cells. In xenograft models bearing MSLN-positive tumors, anti-MSLN CAR-like NK cells exhibited significant antitumor activity, with favorable tolerability and no significant body weight loss or toxicity. Notably, anti-MSLN uCAR-like NK cells, which integrate a tumor-penetrating peptide, displayed enhanced intratumor penetration and superior therapeutic efficacy. Overall, this study establishes a modular, nongenetically engineered uCAR-like NK platform that couples targeted recognition with enhanced tissue access. These findings highlight the potential of anti-MSLN CAR-like NK cells, particularly uCAR-like NK cells with enhanced tumor penetration, as promising therapeutic strategies for MSLN-positive solid tumors and lay the foundation for future clinical applications.

> **中文摘要：**
> 尽管自然杀伤（NK）细胞具有固有的细胞毒性，但由于其缺乏肿瘤特异性靶向能力以及对实体瘤的有限浸润能力，其临床应用常受限制。为克服这些局限性，我们开发了抗间皮素（MSLN）的uCAR样NK细胞，其旨在同时增强靶向特异性和肿瘤浸润能力，从而提高基于NK细胞治疗的抗肿瘤效应。我们利用SpyTag/SpyCatcher系统构建、纯化并验证了一个四价双特异性细胞连接器（MSLN×CD16A）。经IL-12、IL-15和IL-18诱导的细胞因子诱导记忆样NK细胞，与MSLN×CD16A预复合以生成抗MSLN CAR样NK细胞。为进一步增强肿瘤穿透力，将肿瘤穿透肽uCendR整合入该系统，构建出抗MSLN uCAR样NK细胞。体外实验显示，抗MSLN CAR样NK细胞可通过与MSLN×CD16A的稳定结合，对MSLN阳性肿瘤细胞表现出选择性细胞毒性，同时避免杀伤MSLN阴性细胞。在携带MSLN阳性肿瘤的异种移植模型中，抗MSLN CAR样NK细胞表现出显著的抗肿瘤活性，具有良好的耐受性，且未引起体重下降或明显毒性。值得注意的是，整合肿瘤穿透肽的抗MSLN uCAR样NK细胞表现出增强的肿瘤内渗透性和更优的治疗效果。总体而言，本研究建立了一个模块化、非基因工程化的uCAR样NK平台，该平台结合了靶向识别与增强的组织可达性。这些发现强调了抗MSLN CAR样NK细胞，尤其是具有增强肿瘤穿透能力的uCAR样NK细胞，作为治疗MSLN阳性实体瘤的潜在有前景策略，并为未来临床应用奠定了基础。

### 第二部分 AI 大师评价

本研究旨在开发一种融合靶向识别与组织穿透功能的NK细胞治疗新平台，通过构建抗MSLN的uCAR样NK细胞，克服传统NK疗法对实体瘤靶向与浸润不足的限制。作者采用SpyTag/SpyCatcher技术和双特异性连接器实现非基因工程化增强设计，并引入uCendR肽以提高肿瘤穿透力。实验结果显示该系统在体内外均具选择性杀伤MSLN阳性肿瘤且具良好安全性，显示出显著疗效。创新点在于模块化、可调控的设计模式，局限性在于仍需进一步临床验证其长期安全性与稳定性。

---

## 18. 基因组范围CRISPR-Cas9筛选揭示ELF2缺失驱动视网膜母细胞瘤的托泊替康耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436498)
**期刊：** Cell death & disease
**PMID：** 41436498
**DOI：** 10.1038/s41419-025-08335-z

### 第一部分 原文与翻译

**英文原标题：** Loss of ELF2 drives topotecan resistance in retinoblastoma revealed by genome-wide CRISPR-Cas9 screening.

> **英文摘要：**
> The topoisomerase I inhibitor topotecan is an effective chemotherapeutic agent for retinoblastoma; however, treatment resistance remains a major clinical challenge, and its mechanisms remain elusive. Using genome-wide CRISPR-Cas9 knockout screening, we identified ELF2 as a key gene involved in topotecan resistance. Here, we show that surviving retinoblastoma cells exposed to topotecan showed progressively decreased ELF2 expression, accompanied by reduced apoptosis. In a mouse xenograft model, ELF2 disruption diminished the antitumor efficacy of topotecan, with ELF2-knockout cells exhibiting reduced topotecan-induced apoptosis. RNA sequencing further revealed that the MT-CYB pathway, associated with ATP synthesis, contributes to ELF2-mediated resistance. Importantly, clinical analysis demonstrated a correlation between ELF2 expression and tumor volume in retinoblastoma patients treated with topotecan. Together, these findings interrogate the mechanisms underlying topotecan resistance in retinoblastoma and suggest ELF2 as a potential therapeutic target to overcome drug resistance.

> **中文摘要：**
> 拓扑异构酶I抑制剂托泊替康是治疗视网膜母细胞瘤的有效化疗药物；然而，治疗耐药仍是一个主要的临床挑战，其机制尚不清楚。通过全基因组CRISPR-Cas9敲除筛选，我们鉴定出ELF2是参与托泊替康耐药的关键基因。在本研究中，我们显示，经托泊替康处理后存活的视网膜母细胞瘤细胞表现出ELF2表达逐渐降低，并伴随凋亡减少。在小鼠异种移植模型中，ELF2的破坏削弱了托泊替康的抗肿瘤效力，且ELF2敲除细胞表现出托泊替康诱导的凋亡减少。RNA测序进一步揭示，与ATP合成相关的MT-CYB通路参与了ELF2介导的耐药性。重要的是，临床分析显示，在接受托泊替康治疗的视网膜母细胞瘤患者中，ELF2表达与肿瘤体积呈相关。综上所述，这些发现揭示了托泊替康耐药的分子机制，并提示ELF2可作为克服药物耐受的潜在治疗靶点。

### 第二部分 AI 大师评价

该研究以CRISPR-Cas9全基因组筛选为核心技术手段，系统揭示了ELF2缺失在视网膜母细胞瘤托泊替康耐药中的关键作用。研究结合细胞实验、小鼠异种移植模型及临床相关性分析，提出MT-CYB通路在能量代谢调控中的重要贡献。该成果为理解化疗耐药的分子机制提供了新视角，并为靶向ELF2以逆转耐药性提供了潜在策略。其创新性在于从基因筛选到机制验证的多层整合，局限性在于临床样本量和转化验证仍需进一步加强。

---

## 19. 时间性基因调控实现气体囊泡的可控表达并维持细菌活性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436476)
**期刊：** Nature communications
**PMID：** 41436476
**DOI：** 10.1038/s41467-025-67667-8

### 第一部分 原文与翻译

**英文原标题：** Temporal gene regulation enables controlled expression of gas vesicles and preserves bacterial viability.

> **英文摘要：**
> Gas vesicles (GVs) are genetically encodable, air-filled protein nanostructures that have rapidly emerged as a versatile platform for biomedical imaging, cell tracking, and therapeutic delivery. However, in non-native hosts such as Escherichia coli, heterologous expression is hampered by a complex assembly involving ~10 proteins, provoking proteotoxic stress and impaired growth. Here we report a reproducible drop in cell density and viability 8-16 h after GV induction. To address these, we develop a dual-inducer transcriptional system that orthogonally controls assembly factors and the shell protein GvpA2 over a range of stoichiometries. Sequential expression by initiating assembly factors before GvpA2 restores growth without compromising GV production. We further show that the interval between inductions tunes both GV yield and cellular stress. Orthogonal decoupling plus a ~2-3 h head-start for assembly factors prevents proteotoxicity, preserves yields, and restores viability, establishing a generalizable temporal-stoichiometric design for heterologous expression of multimeric protein nanostructures.

> **中文摘要：**
> 气体囊泡（GVs）是一种可通过基因编码的、充满空气的蛋白质纳米结构，已迅速成为生物医学成像、细胞追踪和治疗性递送的多功能平台。然而，在诸如大肠杆菌等非天然宿主中，其异源表达受到复杂组装过程的限制，该过程涉及约10种蛋白质，导致蛋白毒性应激和生长受损。本文报告在GV诱导后8–16小时内，细胞密度和活性可重复性下降。为应对这一问题，我们开发了一种双诱导转录系统，可在不同化学计量范围内正交调控组装因子和壳蛋白GvpA2。通过在GvpA2之前启动组装因子的顺序表达，可在不影响GV产量的前提下恢复细胞生长。我们进一步表明，诱导间隔可调控GV产量及细胞应激水平。正交解耦并给予组装因子约2–3小时的提前启动可防止蛋白毒性、保持产量并恢复活性，从而建立了一种可推广的时间–化学计量学设计，用于多聚蛋白纳米结构的异源表达。

### 第二部分 AI 大师评价

该研究旨在解决气体囊泡在非天然宿主中异源表达受限的问题。作者构建了一个双诱导转录系统，能够独立调控组装因子与壳蛋白的表达时序与比例，并通过时序优化恢复细胞生长与活性。结果表明，提前诱导组装因子可显著降低蛋白毒性压力并提高表达稳定性。该工作创新性地提出了一种时间–化学计量优化策略，为多亚基蛋白纳米结构的精准调控提供了可推广的设计框架，但仍需进一步验证其在更复杂生物系统中的通用性。

---

## 20. 通过细胞间通信网络利用工程化线粒体实现加速传输与递送

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436474)
**期刊：** Nature communications
**PMID：** 41436474
**DOI：** 10.1038/s41467-025-67837-8

### 第一部分 原文与翻译

**英文原标题：** Leveraging engineered mitochondria through intercellular communication network for accelerated transport and delivery.

> **英文摘要：**
> Inspired by the non-transmembrane transfer of mitochondria in cell-to-cell communications, herein, we report an original exploration to accelerate mitochondrial intercellular transport, and its application to exogenous cargo delivery. We discover that deliberate PINK1-targeted mitophagy downregulation elevates mitochondrial transit capacity via multifaceted drivers-morphological adaptation, metabolic reprogramming, and respiratory enhancement. Capitalizing on this, we engineer high-speed mitochondrial vehicles for photosensitizer hitchhiking, with spatiotemporal tracking elucidating its dynamic intercellular transit and physiological impacts. Through mitochondria's communication network-tunneling nanotubes (TNTs), the mitochondria-photosensitizer cotransporter achieves reinforced intercellular delivery, thereby inducing deep tumor penetration and enhanced photodynamic killing. Our work establishes a transformative mitochondria-hitchhiking platform for overcoming biological barriers in drug delivery and provides mechanistic insights into manipulating intercellular organelle transport for therapeutic applications.

> **中文摘要：**
> 受到细胞间通信中线粒体非跨膜转移现象的启发，本文报道了一项旨在加速线粒体细胞间运输及其在外源性货物递送中应用的原创性探索。我们发现，有意下调以PINK1为靶点的线粒体自噬可通过多重机制——形态适应、代谢重编程与呼吸增强——提升线粒体的传递能力。基于此，我们构建了用于光敏剂搭载的高速线粒体载体，并通过时空追踪阐明了其动态的细胞间转移过程及生理影响。借助线粒体的通信网络——隧道纳米管（TNTs），线粒体-光敏剂共转运系统实现了强化的细胞间递送，从而诱导深度肿瘤渗透并增强光动力杀伤效应。本研究建立了一种具有变革意义的线粒体“搭载”平台，以克服药物递送中的生物学屏障，并为操控细胞器间运输以用于治疗提供了机制性见解。

### 第二部分 AI 大师评价

该研究以细胞间线粒体转移为灵感，创新性地通过调控PINK1介导的线粒体自噬来提升线粒体跨细胞运输效率。作者构建了可搭载光敏剂的高速线粒体载体，并通过时空追踪证实其有效的细胞间传递和增强的肿瘤穿透能力。研究不仅展示了线粒体在药物递送中的新潜力，也揭示了可操控的细胞器互作新机制，具有重要的生物医学应用前景。局限性可能在于体系复杂性及临床转化验证的需要。

---

## 21. 4EHP 和 NELF-E 在果蝇疾病模型中调控 ATF4 的生理性诱导及蛋白稳态。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436469)
**期刊：** Nature communications
**PMID：** 41436469
**DOI：** 10.1038/s41467-025-67357-5

### 第一部分 原文与翻译

**英文原标题：** 4EHP and NELF-E regulate physiological ATF4 induction and proteostasis in disease models of Drosophila.

> **英文摘要：**
> Cells adapt to proteostatic and metabolic stresses, in part, through stress activated eIF2α kinases that stimulate the translation of ATF4. Stress-induced ATF4 translation is regulated through elements at ATF4 mRNA's 5' leader. In addition to eIF2α kinases, ATF4 induction requires other regulators that remain poorly understood. Here, we report an ATF4 regulatory network consisting of eIF4E-Homologous Protein (4EHP), NELF-E, the 40S ribosome, and eIF3 subunits. Specifically, we found that the mRNA cap-binding protein, 4EHP, was required for ATF4 signaling in the Drosophila larval fat body and in disease models associated with abnormal ATF4 signaling. NELF-E mRNA, encoding a regulator of pol II-mediated transcription, was identified as a top interactor of 4EHP in a TRIBE (Targets of RNA Binding through Editing) screen. Quantitative proteomics analysis revealed that the knockdown of NELF-E or 4EHP commonly reduced several subunits of the 40S ribosome (RpS) and the eIF3 translation initiation factor. Moreover, reduction of NELF-E, 4EHP, RpS12, eIF3l, or eIF3h suppressed the expression of ATF4 and its target genes. These results uncover a previously unrecognized ATF4 regulatory network consisting of 4EHP and NELF-E that impacts proteostasis during normal development and in disease models.

> **中文摘要：**
> 细胞通过由应激激活的 eIF2α 激酶刺激 ATF4 翻译，部分地适应蛋白质稳态和代谢应激。应激诱导的 ATF4 翻译受 ATF4 mRNA 5' 端引导区的调控元件控制。除 eIF2α 激酶外，ATF4 的诱导还需要其他尚不完全了解的调控因子。在此，我们报道了一个由 eIF4E 同源蛋白（4EHP）、NELF-E、40S 核糖体和 eIF3 亚基组成的 ATF4 调控网络。具体而言，我们发现 mRNA 帽结合蛋白 4EHP 对果蝇幼虫脂肪体中的 ATF4 信号传导以及与异常 ATF4 信号相关的疾病模型是必需的。NELF-E mRNA 编码一种介导 RNA 聚合酶 II 转录调控的因子，在 TRIBE（通过编辑识别 RNA 结合靶标）筛选中被鉴定为 4EHP 的重要互作物。定量蛋白质组学分析显示，敲低 NELF-E 或 4EHP 会共同减少多个 40S 核糖体（RpS）和 eIF3 翻译起始因子的亚基。此外，降低 NELF-E、4EHP、RpS12、eIF3l 或 eIF3h 水平会抑制 ATF4 及其靶基因的表达。这些结果揭示了一个此前未被认识的由 4EHP 和 NELF-E 组成的 ATF4 调控网络，该网络在正常发育和疾病模型中影响蛋白稳态。

### 第二部分 AI 大师评价

本研究阐明了一个此前未被充分认识的 ATF4 调控网络，揭示 4EHP 与 NELF-E 在果蝇发育及疾病状态下对蛋白稳态调控的重要作用。作者综合采用 TRIBE 筛选和定量蛋白质组学等多种技术手段，系统解析了其对 40S 核糖体与 eIF3 起始因子的共同影响。研究创新性地将转录调控因子 NELF-E 与蛋白翻译控制联系起来，为理解应激性翻译调控机制提供了新思路。尽管研究基于模型生物果蝇，其跨物种适用性仍待进一步验证。

---

## 22. 靶向疾病与治疗中的泛素化作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436460)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41436460
**DOI：** 10.1038/s41392-025-02392-8

### 第一部分 原文与翻译

**英文原标题：** Targeting ubiquitination in disease and therapy.

> **英文摘要：**
> Ubiquitination, a critical posttranslational modification (PTM), involves the enzymatic covalent attachment of ubiquitin to target proteins. This process is fundamental for maintaining cellular homeostasis and regulating key biological functions. The ubiquitination pathway, orchestrated by ubiquitin and its associated enzymes, offers remarkable versatility, acting as a cellular sentinel to ensure precise spatiotemporal control of essential molecular processes. Importantly, the components and mechanisms of ubiquitination can be finely tuned in various ways. Dysregulation of this system can disrupt normal biological processes and contribute to the development of various serious human diseases. These findings underscore the importance of investigating ubiquitination to understand disease mechanisms and develop effective treatment strategies. In this review, we summarize the historical developments and key milestones in ubiquitination research, with a focus on its roles in both health and disease. We explore the components and mechanisms involved, the relevant signaling pathways and their crosstalk, and the multilayered regulatory functions of ubiquitination under physiological and pathological conditions. The pathological contexts discussed include cancer, neurodegenerative disorders, cardiovascular diseases, inflammatory conditions, autoinflammatory disorders and developmental disorders. Enhancing our understanding of ubiquitination could provide novel insights into disease pathogenesis and identify new therapeutic targets. We also highlight emerging strategies for cancer treatment, such as proteolysis-targeting chimeras (PROTACs) and molecular glues. Furthermore, we review therapeutic targets and recent progress in clinical research, including ongoing clinical trials and FDA-approved drugs, aimed at leveraging the ubiquitination pathway for disease treatment.

> **中文摘要：**
> 泛素化是一种关键的翻译后修饰（PTM），涉及通过酶促反应将泛素共价附着于靶蛋白上。该过程对于维持细胞稳态和调控关键生物功能至关重要。由泛素及其相关酶所协调的泛素化通路具有显著的多功能性，作为细胞的“哨兵”，确保关键分子过程的精确时空调控。重要的是，泛素化的组成成分和机制可以通过多种方式被精细调节。该系统的失调会破坏正常的生物过程，并促成多种严重人类疾病的发生。这些发现强调了研究泛素化在理解疾病机制和开发有效治疗策略方面的重要性。在本综述中，我们总结了泛素化研究的历史发展与关键里程碑，着重探讨其在健康与疾病中的作用。我们讨论了相关的组成成分与机制、信号通路及其交叉调控，以及泛素化在生理与病理条件下的多层次调节功能。所涉及的病理背景包括癌症、神经退行性疾病、心血管疾病、炎症性疾病、自身炎性疾病和发育障碍。加深对泛素化的理解有助于为疾病发病机制提供新的见解，并发现新的治疗靶点。我们还重点介绍了癌症治疗中的新兴策略，如蛋白降解靶向嵌合体（PROTACs）和分子胶。此外，我们回顾了以泛素化通路为靶点的治疗手段及临床研究的最新进展，包括正在进行的临床试验和已获 FDA 批准的药物，这些研究旨在利用泛素化途径进行疾病治疗。

### 第二部分 AI 大师评价

本文以综述形式系统梳理了泛素化在细胞调控与疾病机制中的关键作用，强调其作为维持蛋白稳态与信号转导枢纽的生物学意义。作者不仅回顾了泛素化研究的发展历程，还总结了其在多种疾病中的病理角色及潜在治疗靶点。研究突出介绍了基于泛素化机制的新型抗肿瘤疗法，包括 PROTACs 与分子胶，展示了该领域的前沿进展。该综述具有较强的学术整合性与临床转化视角，但其系统性综述性质使得实验验证和机制深度探讨仍有拓展空间。

---

## 23. GPR4通过LOXL2介导的细胞外基质重塑促进结肠癌中的免疫排斥。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436455)
**期刊：** Nature communications
**PMID：** 41436455
**DOI：** 10.1038/s41467-025-67967-z

### 第一部分 原文与翻译

**英文原标题：** GPR4 promotes immune exclusion in colon cancer through LOXL2-mediated extracellular matrix remodeling.

> **英文摘要：**
> Immune exclusion is associated with adverse prognosis in tumors, and this phenomenon may be facilitated by a physical barrier constituted by the extracellular matrix (ECM). Hypoxia and acidity promote immune exclusion, however the detailed mechanism remains unclear. This study demonstrate that G-protein-coupled-receptor-4 (GPR4), as a proton sensor, induces immune exclusion in colon cancer by promoting collagen fiber alignment and deposition. Specifically, GPR4 facilitates collagen alignment via LOXL2 regulation and enhances collagen I by modulating TGF-β, both mediated by the JAK2/STAT3 pathway. We further validate our findings in a male animal model, observing that elevated GPR4 expression in colon cancer results in an immune-excluded microenvironment. Inhibition of the JAK2/STAT3 pathway and LOXL2 function effectively reverse immune exclusion and enhance immunotherapy efficacy. Collectively, our findings elucidate a mechanism of immune exclusion and propose a potential target for improving the therapeutic efficacy of immunotherapy through the remodeling of the tumor ECM.

> **中文摘要：**
> 免疫排斥与肿瘤的不良预后相关，而这一现象可能由细胞外基质（ECM）形成的物理屏障所促进。缺氧和酸性环境可促进免疫排斥，但其详细机制尚不清楚。本研究表明，作为质子传感器的G蛋白偶联受体4（GPR4）通过促进胶原纤维的排列和沉积，在结肠癌中诱导免疫排斥。具体而言，GPR4通过调控LOXL2促进胶原纤维排列，并通过调节TGF-β增强I型胶原表达，两者均由JAK2/STAT3信号通路介导。我们进一步在雄性动物模型中验证了这些发现，观察到结肠癌中GPR4表达升高会导致免疫排斥性的微环境。抑制JAK2/STAT3通路和LOXL2功能可有效逆转免疫排斥，并增强免疫治疗的疗效。总体而言，本研究阐明了免疫排斥的机制，并提出通过肿瘤ECM重塑改善免疫治疗疗效的潜在治疗靶点。

### 第二部分 AI 大师评价

该研究揭示了GPR4通过调控LOXL2介导的细胞外基质重塑促进结肠癌免疫排斥的新机制。研究者系统阐明了GPR4、JAK2/STAT3通路及TGF-β信号在促进胶原排列与沉积中的作用，并在动物模型中验证了其功能。结果强调抑制GPR4相关通路可改善免疫治疗反应，具有重要的临床转化潜力。该工作创新性地将肿瘤酸性微环境信号与免疫排斥机制连接起来，但其在不同肿瘤类型中的普适性仍需进一步验证。

---

## 24. 单细胞RNA测序揭示化疗后细胞静息与衰老状态的连续谱及不同衰老类型。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436452)
**期刊：** Nature communications
**PMID：** 41436452
**DOI：** 10.1038/s41467-025-66836-z

### 第一部分 原文与翻译

**英文原标题：** Single-cell RNA sequencing reveals a quiescence-senescence continuum and distinct senotypes following chemotherapy.

> **英文摘要：**
> Quiescence (reversible cell-cycle arrest) and senescence (irreversible arrest) are challenging to distinguish due to a lack of specific biomarkers, yet both arise simultaneously after chemotherapy. While senescence suppresses tumors by limiting proliferation and recruiting the immune system, quiescent cancer cells evade future therapies and may resume proliferation. Here, we pair time-lapse imaging of cell-cycle dynamics with single-cell RNA sequencing after etoposide treatment to differentiate these states, linking heterogeneous cell-cycle phenotypes to the transcriptomic landscape. We identify diverse senescent types (senotypes) and link them to two arrest pathways - a gradual path arising after a standard mitosis-to-G0 transition, and an alternative direct path driven by a mitotic slip. Using pseudotime trajectory analysis, we find that senescent phenotypes begin to manifest early and gradually along the first trajectory, even in shallow quiescent cells. These data support a model wherein, following chemotherapy, quiescence and senescence exist on a continuum of cell-cycle withdrawal at a transcriptome-wide level.

> **中文摘要：**
> 静息（可逆的细胞周期停滞）和衰老（不可逆的停滞）由于缺乏特异性生物标志物而难以区分，但两者在化疗后会同时出现。尽管细胞衰老通过限制增殖和募集免疫系统来抑制肿瘤，但静息的癌细胞能够逃避后续治疗并可能重新进入增殖状态。在本研究中，我们结合依托泊苷处理后的细胞周期动态时间序列成像与单细胞RNA测序，以区分这些细胞状态，并将异质的细胞周期表型与转录组特征相联系。我们鉴定出多种不同的衰老类型（senotypes），并将其关联到两种停滞途径——一种是经过标准有丝分裂到G0转变而产生的渐进性途径，另一种是由有丝分裂滑移驱动的直接途径。通过伪时间轨迹分析，我们发现衰老表型在第一条轨迹上从早期开始逐步显现，甚至在浅层静息细胞中亦然。这些数据支持这样一个模型：在化疗后，静息与衰老在转录组层面上形成一个连续的细胞周期退出谱。

### 第二部分 AI 大师评价

本研究利用单细胞RNA测序结合时间序列成像的方法，系统解析了化疗后细胞从静息到衰老的连续变化谱。作者不仅区分了不同的衰老类型，还揭示了它们对应的两条停滞通路及其分子动态特征。该工作创新性地提出了静息与衰老并非截然分离，而是存在于一个转录组水平的连续体中，为理解化疗后肿瘤细胞命运提供了新模型和潜在干预靶点。其局限性在于模型依赖体外实验系统，尚需进一步验证其在临床组织中的普适性。

---

## 25. 22,710份人类微生物组宏基因组的荟萃分析定义了口腔-肠道微生物富集评分及其与宿主健康和疾病的关联

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436448)
**期刊：** Nature communications
**PMID：** 41436448
**DOI：** 10.1038/s41467-025-66888-1

### 第一部分 原文与翻译

**英文原标题：** Meta-analysis of 22,710 human microbiome metagenomes defines an oral-to-gut microbial enrichment score and associations with host health and disease.

> **英文摘要：**
> Large public datasets of the human microbiome now exist but combining them for large-scale analysis is difficult due to a lack of standardization. We developed curatedMetagenomicData (cMD) 3, a uniformly processed collection of over 22,000 human microbiome samples with manually curated metadata from 94 studies and 42 countries. This large and diverse resource allows for meta-analysis of the links between microbes and human health. Through meta-analysis, we identified hundreds of microbial species and thousands of microbial functions significantly associated with a person's sex, age, body mass index, and disease status, and catalog these as references. We developed an "oral enrichment score" (OES) based on the relative abundance of bacteria typically found in the oral cavity and not in the gut. Higher OES in the gut is a consistent feature in individuals with disease, suggesting that the relative abundance of oral bacteria in the gut is a simple and quantifiable signal of altered microbiome health. These analyses identify modest but widely shared patterns in human microbiomes, serving as a reproducible and readily updatable reference.

> **中文摘要：**
> 目前已存在大型的人类微生物组公共数据集，但由于缺乏标准化，将这些数据整合用于大规模分析仍然困难。我们开发了 curatedMetagenomicData（cMD）3，这是一个经过统一处理、包含来自94项研究和42个国家的超过22,000份人类微生物组样本的集合，并附有人工校对的元数据。该庞大而多样的资源使得能对微生物与人类健康之间的联系进行荟萃分析。通过荟萃分析，我们确定了数百种与个体性别、年龄、体重指数和疾病状态显著相关的微生物物种，以及数千种微生物功能，并建立了相应参考目录。我们基于典型存在于口腔而非肠道的细菌相对丰度，开发了“口腔富集评分”（OES）。在肠道中较高的 OES 是疾病个体的一致特征，提示口腔来源细菌在肠道中的相对丰度可作为微生物组健康失调的简单且可量化信号。这些分析揭示了人类微生物组中虽小但普遍存在的模式，为建立可重复且易更新的参考体系提供了基础。

### 第二部分 AI 大师评价

本研究利用超过两万例人类微生物组样本，通过大规模荟萃分析系统刻画了微生物与宿主健康之间的全局联系。研究团队构建了统一处理的数据库 cMD3，并提出基于口腔菌群在肠道相对丰度的“口腔富集评分”。这一指标揭示了肠道健康失调与口腔来源菌入侵的潜在关联，具有重要的生物标志物潜力。研究亮点在于数据规模宏大、处理标准一致，但其统计关联仍需机制性实验验证以强化生物学解释。

---

## 26. 前列腺癌细胞在发生转移扩散时趋同为炎症样状态

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436446)
**期刊：** Nature communications
**PMID：** 41436446
**DOI：** 10.1038/s41467-025-67856-5

### 第一部分 原文与翻译

**英文原标题：** Prostate cancer cells converge to an inflammatory-like state upon metastatic dissemination.

> **英文摘要：**
> Identifying drivers of cancer progression to guide treatment selection is hindered by our limited understanding of tumor heterogeneity and its impact on tumor evolution. Here, we delineate the phenotypic variability across ~300,000 cells collected from multiple tumor loci in primary prostate and matched locoregional metastases using single-cell chromatin accessibility and gene expression sequencing. We find inter-patient heterogeneity to be confined to malignant populations. Within individual tumor loci, we see phenotypic heterogeneity among malignant cell populations despite a shared clonal genotypic architecture. We also observe that malignant cell populations disseminating to locoregional lymph nodes mirror the clonal architecture and phenotypic heterogeneity across primary tumor loci, while shifting from canonical prostate-cancer states to non-canonical inflammatory-like states. Our findings suggest a bottleneck imposed during the dissemination process, funneling prostate cancer cells toward an inflammatory-like cell state. These insights into the interplay between phenotypic identity and clonal architecture refine our understanding of prostate cancer progression and suggest that convergence of cancer cells towards an inflammatory-like state underlies dissemination to lymph nodes, offering a critical framework for future studies into prostate cancer metastatic potential.

> **中文摘要：**
> 由于我们对肿瘤异质性及其对肿瘤演化影响的理解有限，识别癌症进展的驱动因素以指导治疗选择仍具有挑战。本文利用单细胞染色质可及性测序和基因表达测序，对来自原发前列腺肿瘤及其相匹配的局部区域转移灶的约30万个细胞进行了分析，以描绘表型变异性。我们发现，患者间的异质性主要局限于恶性细胞群体。在单个肿瘤灶内，尽管存在共同的克隆性基因型结构，我们仍观察到恶性细胞群体之间的表型异质性。我们还发现，扩散至局部淋巴结的恶性细胞群体在克隆结构和表型异质性上与原发肿瘤灶相似，但其状态从典型的前列腺癌状态转变为非典型的炎症样状态。我们的发现提示，在扩散过程中存在一个瓶颈，使前列腺癌细胞趋向于炎症样细胞状态。这些关于表型特征与克隆结构相互作用的洞见，细化了我们对前列腺癌进展机制的理解，并提示癌细胞向炎症样状态的趋同可能是其向淋巴结转移的基础，为未来研究前列腺癌转移潜能提供了重要框架。

### 第二部分 AI 大师评价

本研究旨在揭示前列腺癌在转移扩散过程中的表型演化特征。作者基于单细胞染色质可及性与基因表达测序，系统分析了来源于原发灶与局部转移灶的大规模细胞群，发现癌细胞在转移过程中趋同为炎症样状态。研究创新地展示了克隆结构与表型状态之间的动态耦合关系，提出转移扩散中的“炎症样趋同”可能是关键病理节点。尽管结果主要基于局部转移模型，仍为前列腺癌转移机制提供了重要理论依据与研究框架。

---

## 27. 克隆进化与转录可塑性塑造前列腺癌转移扩散途径

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436444)
**期刊：** Nature communications
**PMID：** 41436444
**DOI：** 10.1038/s41467-025-66704-w

### 第一部分 原文与翻译

**英文原标题：** Clonal evolution and transcriptional plasticity shape metastatic dissemination routes in prostate cancer.

> **英文摘要：**
> Prostate cancer is a highly heterogeneous disease, driven by genomic and transcriptional changes that impact disease progression and metastatic potential. The interplay between clonal evolution, transcriptional plasticity, and tumour microenvironment is, however, poorly understood. Here, we leverage and integrate single-nuclei RNA sequencing and whole-genome sequencing from 43 spatially distinct tumour samples from five patients with locally advanced prostate cancer to reconstruct clonal evolution trajectories and transcriptional changes driving metastasis at single-cell resolution. We find extensive clonal heterogeneity, including both monophyletic and polyphyletic metastatic dissemination, and ongoing clonal evolution in the primary tumour after metastatic spread. Metastatic seeding converges on disease trajectories involving both genomic and transcriptional changes, including androgen receptor independence and activation of estrogen-, WNT- and JAK-STAT- pathway activity, in spatially distinct areas. Our findings suggest an intricate interplay between clonal evolution and cellular plasticity driving metastatic seeding and point toward more integrative prognostic markers for improved patient management.

> **中文摘要：**
> 前列腺癌是一种高度异质性的疾病，其进展和转移潜能受基因组和转录水平变化驱动。然而，克隆进化、转录可塑性与肿瘤微环境之间的相互作用仍知之甚少。本研究整合并利用来自5例局部晚期前列腺癌患者的43个空间异质性肿瘤样本的单核RNA测序和全基因组测序数据，在单细胞分辨率下重建驱动转移的克隆进化轨迹与转录变化。研究发现存在广泛的克隆异质性，包括单系性与多系性转移扩散，并且在转移发生后，原发肿瘤中仍存在持续的克隆进化。转移的播种过程趋同于同时涉及基因组与转录变化的疾病轨迹，其中包括雄激素受体独立性以及雌激素、WNT 和 JAK-STAT 通路活性的激活，这些变化分布于空间上不同的区域。研究结果揭示了克隆进化与细胞可塑性之间复杂的相互作用共同驱动转移播种，并提示应发展更具整合性的预后标志物以改善患者管理。

### 第二部分 AI 大师评价

本研究通过整合单核RNA测序与全基因组测序，从空间与克隆演化层面系统解析了前列腺癌转移发生的机制。研究揭示了原发肿瘤在转移后仍保持动态的克隆进化，且不同区域的转录状态体现出高度可塑性。其发现雄激素受体独立性与多个信号通路的激活可能是转移扩散的关键特征，进一步强调了基因组与转录层面协同调控的重要性。研究为理解前列腺癌进展提供了新的系统性视角，但受样本量及患者个体差异限制，仍需更大规模研究验证。

---

## 28. 更正：circ_0003215 的 N6-甲基腺苷修饰通过 miR-663b/DLG4/G6PD 轴抑制结直肠癌的磷酸戊糖途径及恶性进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436443)
**期刊：** Cell death & disease
**PMID：** 41436443
**DOI：** 10.1038/s41419-025-08199-3

### 第一部分 原文与翻译

**英文原标题：** Correction: N6-methyladenosine modification of circ_0003215 suppresses the pentose phosphate pathway and malignancy of colorectal cancer through the miR-663b/DLG4/G6PD axis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本条目为更正声明，涉及 circ_0003215 在结直肠癌中的表观遗传修饰研究。原研究揭示 N6-甲基腺苷修饰通过 miR-663b/DLG4/G6PD 信号轴调控磷酸戊糖途径，从而影响肿瘤的代谢与恶性程度。这一发现反映出环状 RNA 以及 RNA 修饰在肿瘤能量代谢中的潜在关键作用。该更正提示作者对原文部分内容进行修订，保证数据与结论的严谨性。

---

## 29. 更正：TAB182通过FHL2依赖性机制促进β-连环蛋白核转位，从而加剧食管鳞状细胞癌的进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436441)
**期刊：** Cell death & disease
**PMID：** 41436441
**DOI：** 10.1038/s41419-025-08077-y

### 第一部分 原文与翻译

**英文原标题：** Correction: TAB182 aggravates progression of esophageal squamous cell carcinoma by enhancing β-catenin nuclear translocation through FHL2 dependent manner.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文是一篇关于TAB182在食管鳞状细胞癌进展中的作用研究的更正通知。标题显示TAB182通过FHL2依赖机制增强β-连环蛋白的核转位，从而促进肿瘤恶化。尽管本文无摘要，原研究可能揭示了癌症信号转导的新调控环节。该更正提示作者在数据或结论中进行了修订，以确保研究结果的准确性与可重复性。

---

## 30. IRX3-CDK14 轴通过调控 LRP6 介导的经典 Wnt/β-连环蛋白通路促进胶质母细胞瘤进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436436)
**期刊：** Cell death & disease
**PMID：** 41436436
**DOI：** 10.1038/s41419-025-08387-1

### 第一部分 原文与翻译

**英文原标题：** IRX3-CDK14 axis promotes glioblastoma progression by regulating LRP6-mediated canonical Wnt/β-catenin pathway.

> **英文摘要：**
> Iroquois Homeobox 3 (IRX3), a highly conserved member of the Iroquois homeobox gene family, has been implicated in obesity through its regulation of fat mass and obesity-associated (FTO) gene. Emerging evidence indicates that IRX3 plays critical roles in the development of some cancers, but the specific functions and molecular mechanisms of IRX3 in glioblastoma (GBM) remain unknown. Here, we demonstrate that IRX3 is highly expressed in GBM and significantly correlated with poor prognosis of patients. IRX3 promotes cell proliferation, colony formation, migration, and invasion in vitro and brain tumor growth in vivo. Mechanistically, IRX3 promotes the transcription of CDK14 (Cyclin Dependent Kinase 14) by binding to its promoter, which in turn stabilizes β-catenin expression through restraining its ubiquitination degradation, thereby activating the canonical Wnt/β-catenin pathway and promoting GBM growth. In addition, we identify LRP6 (LDL receptor-related protein 6) as a crucial regulatory factor in maintaining IRX3-mediated stabilization of β-catenin. Our results demonstrate that IRX3 serves as a promising biomarker for patients with GBM, and targeting the IRX3-CDK14-LRP6 axis may represent a viable treatment approach for GBM.

> **中文摘要：**
> Iroquois 同源盒基因 3（IRX3）是 Iroquois 同源盒基因家族中高度保守的成员，其通过调控与脂肪质量和肥胖相关的 FTO 基因，与肥胖的发生相关。新兴证据显示，IRX3 在某些癌症的发生发展中发挥关键作用，但其在胶质母细胞瘤（GBM）中的具体功能及分子机制仍不清楚。本研究表明，IRX3 在 GBM 中高表达，并与患者的不良预后显著相关。IRX3 能在体外促进细胞增殖、克隆形成、迁移和侵袭，并在体内促进脑肿瘤生长。在机制上，IRX3 通过结合 CDK14（细胞周期依赖性激酶 14）启动子区域促进其转录，而 CDK14 通过抑制 β-连环蛋白的泛素化降解来稳定其表达，从而激活经典的 Wnt/β-连环蛋白信号通路并促进 GBM 生长。此外，我们鉴定出 LRP6（低密度脂蛋白受体相关蛋白 6）是维持 IRX3 介导的 β-连环蛋白稳定化过程中的关键调控因子。我们的研究结果表明，IRX3 可能是 GBM 患者的潜在生物标志物，靶向 IRX3-CDK14-LRP6 轴可能代表一种可行的治疗策略。

### 第二部分 AI 大师评价

该研究旨在阐明 IRX3 在胶质母细胞瘤中的生物学作用及其分子机制。作者通过体内外实验发现 IRX3 通过上调并激活 CDK14，从而稳定 β-连环蛋白并激活经典 Wnt 信号通路，促进肿瘤生长。进一步确定 LRP6 在维持这一信号轴中的关键调控作用。研究揭示了 IRX3-CDK14-LRP6 轴在 GBM 进展中的重要角色，具有潜在的治疗靶点价值，但仍需进一步验证其临床应用可行性。

---

## 31. TNF-α驱动的m6A修饰通过调控依赖HDAC5的超级增强子破坏间充质干细胞的免疫调节功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436435)
**期刊：** Cell death & disease
**PMID：** 41436435
**DOI：** 10.1038/s41419-025-08192-w

### 第一部分 原文与翻译

**英文原标题：** TNF-α-driven m6A modification disrupts the immunoregulatory function of MSCs by regulating HDAC5-dependent super-enhancers.

> **英文摘要：**
> Mesenchymal stem cells (MSCs) are extensively utilised to treat inflammatory diseases because of their strong immunosuppressive functions. However, these functions are strongly affected by the inflammatory microenvironment in vivo, which limits the therapeutic effect of MSCs. The present study demonstrated that TNF-α impairs the immunosuppressive effect of MSCs on T-cell proliferation. Mechanistically, TNF-α treatment decreased the expression of the H3 deacetylase HDAC5 and then led to increased super-enhancer (SE) signals and increased expression of leukaemia inhibitory factor (LIF), which results in the dysfunction of MSCs' immunosuppressive effect. Intravenous infusion of MSCs overexpressing HDAC5 increased therapeutic efficacy in SKG mice with inflammatory arthritis. Notably, TNF-α downregulated HDAC5 by promoting WTAP-mediated m6A modification of HDAC5 mRNAs, which are subsequently regulated by YTHDF2 to reduce mRNA stability. Our results reveal a synergistic epigenetic regulatory mechanism between SEs and m6A modification of MSC immunosuppressive functions and provide a novel strategy to promote the clinical therapeutic potential of MSC infusion in inflammatory diseases.

> **中文摘要：**
> 由于具有强大的免疫抑制功能，间充质干细胞（MSCs）被广泛用于治疗炎症性疾病。然而，这种功能在体内会受到炎症微环境的显著影响，从而限制了MSCs的治疗效果。本研究表明，TNF-α会削弱MSCs对T细胞增殖的免疫抑制作用。在机制上，TNF-α处理降低了组蛋白去乙酰化酶HDAC5的表达，从而增强了超级增强子（SE）信号并上调了白血病抑制因子（LIF）的表达，导致MSCs免疫抑制功能失调。将过表达HDAC5的MSCs经静脉注射入炎性关节炎的SKG小鼠可提高治疗效果。值得注意的是，TNF-α通过促进WTAP介导的HDAC5 mRNA的m6A修饰下调HDAC5表达，随后该修饰由YTHDF2调控以降低mRNA稳定性。我们的研究揭示了超级增强子与m6A修饰在调控MSCs免疫抑制功能中的协同表观遗传调控机制，并为提升MSCs在炎症性疾病中的临床应用潜力提供了新的策略。

### 第二部分 AI 大师评价

本研究通过阐明TNF-α介导的m6A修饰如何调控HDAC5依赖的超级增强子活性，揭示了炎症环境下MSCs免疫调控功能受损的表观遗传机制。研究采用分子机制探讨与动物模型验证相结合的方法，系统揭示了HDAC5作为关键调控枢纽的作用。其创新之处在于发现m6A修饰与超级增强子在MSCs免疫功能中的协同调控关系，为优化干细胞治疗炎症性疾病提供了理论依据。然而，该研究仍受限于动物模型验证，未来需进一步探索其临床可行性与安全性。

---

## 32. 靶向MED23通过抑制代偿性增殖并促进ROS介导的细胞死亡抑制肝细胞癌的发生发展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436431)
**期刊：** Cell death & disease
**PMID：** 41436431
**DOI：** 10.1038/s41419-025-08348-8

### 第一部分 原文与翻译

**英文原标题：** Targeting MED23 inhibits hepatocellular carcinoma development by suppressing compensatory proliferation and facilitating ROS-mediated cell death.

> **英文摘要：**
> Hepatocellular carcinoma (HCC) is frequently linked to compensatory proliferating hepatocytes in damaged livers, yet the underlying molecular mechanisms remain elusive. The Mediator complex precisely coordinates multiple transcription factors and cofactors to regulate diverse physiological and pathological processes. Here, we discovered that Mediator subunit MED23 is involved in the progression of HCC. Both constitutive and inducible liver-specific ablation of Med23 effectively inhibited HCC development in diethylnitrosamine (DEN)-induced HCC mouse models. Mechanistically, MED23 deficiency significantly compromised hepatocyte cell viability by reducing the stability of the NQO1 protein, thereby leading to an increase in reactive oxygen species (ROS) production. Furthermore, MED23 collaborates with the transcription factor RFX5 to regulate a novel enhancer function for IGF2 expression, which thus influences hepatocyte viability and HCC development. Consistently, overexpression of IGF2 in MED23-deficient HCC cells stabilizes NQO1 and partially restores cell growth and reduces apoptosis. Collectively, our findings underscore the significance of the MED23-IGF2-NQO1 axis in HCC progression and propose a novel therapeutic strategy for the treatment of HCC.

> **中文摘要：**
> 肝细胞癌（HCC）常与受损肝脏中代偿性增殖的肝细胞相关，但其潜在分子机制仍不清楚。Mediator复合物通过精确协调多种转录因子和辅助因子，从而调控多种生理和病理过程。本研究发现，Mediator复合物亚基MED23参与了HCC的进展。无论是持续性还是可诱导的肝脏特异性Med23敲除，在二乙基亚硝胺（DEN）诱导的HCC小鼠模型中均能有效抑制肝癌的发展。在机制上，MED23缺失通过降低NQO1蛋白的稳定性显著削弱了肝细胞的存活能力，从而导致活性氧（ROS）水平增加。此外，MED23与转录因子RFX5协同作用，调控IGF2表达的新型增强子功能，从而影响肝细胞活性及肝癌发生。相应地，在MED23缺失的HCC细胞中过表达IGF2能稳定NQO1，并部分恢复细胞增殖与降低凋亡。总体而言，本研究强调了MED23-IGF2-NQO1轴在HCC进展中的重要性，并提出了一种治疗HCC的新策略。

### 第二部分 AI 大师评价

该研究揭示MED23在肝细胞癌进展中的关键调控作用，重点阐明了其通过影响NQO1稳定性及ROS生成来调控肝细胞生存的机制。研究采用了遗传学敲除模型与功能验证实验，证明了MED23与RFX5共同调控IGF2表达，从而形成新的调控轴。结果明确提出了MED23-IGF2-NQO1通路在肝癌发生中的关键作用，为开发靶向MED23的治疗策略提供了新的理论依据。研究创新性显著，但仍需在临床样本中进一步验证其可转化价值。

---

## 33. FUT2通过促进FBXO2介导的NR2F2降解增强胰腺癌放疗的抗肿瘤免疫反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436429)
**期刊：** Cell death & disease
**PMID：** 41436429
**DOI：** 10.1038/s41419-025-08378-2

### 第一部分 原文与翻译

**英文原标题：** FUT2 enhances anti-tumor immunity in pancreatic cancer radiotherapy by driving FBXO2-mediated degradation of NR2F2.

> **英文摘要：**
> Pancreatic ductal adenocarcinoma (PDAC) radiotherapy (RT) resistance is frequently mediated by an immunosuppressive tumor microenvironment (TIME). Utilizing an in vivo CRISPR-Cas9 metabolic enzyme screen, we identified fucosyltransferase 2 (FUT2) as a potent non-catalytic enhancer of RT response. Mechanistically, FUT2 scaffolds the E3 ubiquitin ligase FBXO2, facilitating K362 site-specific ubiquitination and proteasomal degradation of the transcription factor NR2F2. This degradation suppresses expression of the immunosuppressive factor Lipocalin-2 (LCN2), which drives CD8⁺ T cell exhaustion and impedes NK cell infiltration, fostering a radioresistant TIME. Interestingly, we observed that RT could reduce FUT2 transcript levels via an METTL14-mediated m⁶A RNA methylation, while NR2F2 was identified to transcriptionally upregulate METTL14, establishing a feedforward inhibitory loop that sustains FUT2 suppression. Clinically, FUT2 expression positively correlates with CD8⁺ T cell infiltration and prolonged survival in RT-treated PDAC patients. Preclinically, combining RT with LCN2-neutralizing antibodies elicited synergistic anti-tumor immunity. These results unveil FUT2 as a regulator of PDAC radiosensitivity via the FUT2-FBXO2-NR2F2-LCN2 axis, offering a promising therapeutic target to overcome RT resistance.

> **中文摘要：**
> 胰腺导管腺癌（PDAC）的放射治疗（RT）抗性常由免疫抑制性肿瘤微环境（TIME）所介导。通过体内CRISPR-Cas9代谢酶筛查，我们鉴定出岩藻糖基转移酶2（FUT2）是一种强效的非催化型放疗反应增强因子。从机制上看，FUT2可作为E3泛素连接酶FBXO2的支架蛋白，促进转录因子NR2F2在K362位点特异性泛素化及其经蛋白酶体降解。该降解过程抑制了免疫抑制因子脂质运载蛋白2（LCN2）的表达，而LCN2会导致CD8⁺ T细胞衰竭并抑制NK细胞浸润，从而促进放射抗性TIME的形成。有趣的是，我们观察到放疗可通过METTL14介导的m⁶A RNA甲基化降低FUT2转录水平，而NR2F2被鉴定可转录上调METTL14，从而形成一个持续抑制FUT2的前馈性抑制环。在临床上，FUT2的表达与RT治疗PDAC患者中CD8⁺ T细胞浸润及生存期延长呈正相关。在临床前研究中，RT联合LCN2中和抗体能够产生协同的抗肿瘤免疫效应。这些结果揭示了FUT2通过FUT2-FBXO2-NR2F2-LCN2通路调控PDAC放射敏感性，提供了克服放疗抗性的潜在治疗靶点。

### 第二部分 AI 大师评价

本研究聚焦于胰腺导管腺癌放疗抗性机制，通过CRISPR筛查发现FUT2在增强放疗免疫反应中的关键作用。研究阐明FUT2通过支架E3连接酶FBXO2促进NR2F2降解，从而抑制免疫抑制因子LCN2的表达，重塑肿瘤免疫微环境。并揭示了RT-METTL14-NR2F2-FUT2之间的前馈性抑制环，为抵抗放疗抗性提供新的分子靶点。该研究在机制深度和临床转化潜力上具有创新性，但其在不同肿瘤类型中的普适性仍需进一步验证。

---

## 34. 更正：关于“肿瘤相关巨噬细胞来源的外泌体通过TIMP2依赖性血管生成拟态传递miR-193a-5p促进肾细胞癌进展”的更正。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436428)
**期刊：** Cell death & disease
**PMID：** 41436428
**DOI：** 10.1038/s41419-025-08075-0

### 第一部分 原文与翻译

**英文原标题：** Correction: Correction to: Tumor-associated macrophage-derived exosomes transmitting miR-193a-5p promote the progression of renal cell carcinoma via TIMP2-dependent vasculogenic mimicry.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该文为一则更正声明，旨在修订先前关于肿瘤相关巨噬细胞来源外泌体在肾细胞癌血管生成拟态及进展中的分子机制研究。虽然未提供摘要与实验细节，但从标题内容可见，研究聚焦于miR-193a-5p与TIMP2信号轴的调控关系。更正的发布有助于保证原研究结果的准确性与可溯源性，体现了期刊在科研诚信方面的严谨态度。

---

## 35. SPOP 与 HAUSP 双向调控 LZTS2 的泛素化以调节 Wnt 信号通路

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436424)
**期刊：** Cell death & disease
**PMID：** 41436424
**DOI：** 10.1038/s41419-025-08351-z

### 第一部分 原文与翻译

**英文原标题：** SPOP and HAUSP bidirectionally regulate LZTS2 ubiquitination to modulate the Wnt pathway.

> **英文摘要：**
> Colorectal cancer (CRC) is a highly deadly disease worldwide, often characterized by the overactivation of the Wnt pathway. LZTS2 is known to be a tumor suppressor by negatively regulating the Wnt pathway in CRC. However, the mechanisms that control the stability of LZTS2 are not fully understood. In this study, we find that the E3 ligase SPOP promotes ubiquitination-mediated degradation of LZTS2, which is counteracted by the deubiquitinase HAUSP. SPOP and HAUSP compete for binding to the same region of LZTS2, leading to bidirectional regulation of LZTS2 stability. The regulation ultimately impacts the activity of the Wnt pathway. Furthermore, functional analyses reveal that SPOP hinders the tumor-suppressive effects of LZTS2 on CRC cell proliferation and metastasis, whereas HAUSP enhances LZTS2's anti-tumor activity in CRC cells. Taken together, these findings uncover a novel regulatory mechanism of LZTS2 stability, where SPOP and HAUSP play crucial roles in determining the behavior of CRC cells by balancing the ubiquitination and deubiquitination of LZTS2. This discovery may offer new strategies for utilizing LZTS2 as a potential therapeutic target for cancer treatment.

> **中文摘要：**
> 结直肠癌（CRC）是全球范围内高度致死性的疾病，其特征常为 Wnt 信号通路的过度激活。已知 LZTS2 通过负向调控 Wnt 通路在 CRC 中发挥肿瘤抑制因子的作用。然而，控制 LZTS2 稳定性的机制尚未完全阐明。本研究发现，E3 泛素连接酶 SPOP 促进 LZTS2 的泛素化介导降解，而去泛素化酶 HAUSP 则对此过程具有拮抗作用。SPOP 与 HAUSP 竞争结合 LZTS2 的同一区域，从而对 LZTS2 稳定性形成双向调控。该调控最终影响 Wnt 通路的活性。此外，功能分析表明，SPOP 会削弱 LZTS2 对 CRC 细胞增殖与转移的抑制作用，而 HAUSP 则增强 LZTS2 在 CRC 细胞中的抗肿瘤活性。综上所述，这些研究结果揭示了一种全新的 LZTS2 稳定性调控机制，其中 SPOP 与 HAUSP 通过平衡 LZTS2 的泛素化与去泛素化在决定 CRC 细胞行为中发挥关键作用。该发现可能为将 LZTS2 作为潜在癌症治疗靶点提供新的策略。

### 第二部分 AI 大师评价

本研究聚焦于结直肠癌中 LZTS2 稳定性的分子调控机制，揭示了 SPOP 与 HAUSP 在泛素化与去泛素化平衡中的对抗作用。通过机制性分析和功能验证，作者明确了二者如何影响 Wnt 信号活性及肿瘤细胞行为。研究的创新之处在于发现了 LZTS2 稳定性的双向调控模式，为靶向 Wnt 信号通路提供了新的潜在治疗切入点。其局限性在于尚需进一步体内模型验证及临床相关性评估。

---

## 36. 更正：线粒体Lon诱导的线粒体自噬通过内质网-线粒体界面上钙依赖性FUNDC1磷酸化促进缺氧耐受性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436423)
**期刊：** Cell death & disease
**PMID：** 41436423
**DOI：** 10.1038/s41419-025-08273-w

### 第一部分 原文与翻译

**英文原标题：** Correction: Mitochondrial Lon-induced mitophagy benefits hypoxic resistance via Ca-dependent FUNDC1 phosphorylation at the ER-mitochondria interface.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可供参考。

### 第二部分 AI 大师评价

本篇文章为一则更正声明，涉及研究线粒体Lon蛋白介导的线粒体自噬及其通过钙依赖性FUNDC1磷酸化增强缺氧耐受性的机制。原始研究聚焦于细胞应激环境下的线粒体质量控制与能量维持机制。尽管该更正未提供具体摘要，其核心科学问题具有重要的细胞代谢与疾病机制研究意义，有助于完善线粒体功能障碍相关病理的理解。

---

## 37. 针对HSP90 C端二聚体的小分子抑制剂调节自噬，并与mTOR抑制协同作用以杀伤顺铂耐药癌细胞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436422)
**期刊：** Cell death & disease
**PMID：** 41436422
**DOI：** 10.1038/s41419-025-08330-4

### 第一部分 原文与翻译

**英文原标题：** Small-molecule inhibitor of C‑terminal HSP90 dimerization modulates autophagy and functions synergistically with mTOR inhibition to kill cisplatin-resistant cancer cells.

> **英文摘要：**
> A major obstacle for the successful treatment of cancer is the presence or development of resistance mechanisms toward therapeutic intervention. In urothelial cancer, cisplatin-based regimens are still routinely employed, and multiple pathways contribute to chemoresistance. Since the identification of heat shock protein 90 (HSP90) as potential cancer target, various HSP90 inhibitors have been developed and evaluated in clinical trials. However, limited efficacy has been observed, mainly caused by dose-limiting toxicity and the concomitant induction of a cytoprotective heat shock response (HSR). To avoid this effect, inhibitors targeting the C-terminal domain (CTD) of HSP90 that do not elicit an HSR have been put forward. Additionally, the crosstalk between autophagy and HSP90 is currently being explored, since both processes work together in proteostasis, and the modulation of autophagy might be helpful in order to improve the efficacy of HSP90 inhibitors. We demonstrate that the second-generation small-molecule inhibitor VWK147 targeting HSP90 CTD dimerization induces cell death in both cisplatin-sensitive and cisplatin-resistant urothelial carcinoma cells. The treatment with VWK147 in these cells led to the destabilization of classical HSP90 client proteins without triggering an HSR. Additionally, we observe that VWK147 re-sensitizes resistant urothelial carcinoma cells to cisplatin and-in combination with mTOR inhibition-synergistically kills cisplatin-sensitive and -resistant cells, in contrast to what is observed upon treatment with the N-terminal domain-targeting HSP90 inhibitor 17-AAG. This synergy may be explained by VWK147-mediated inhibition of late autophagy events, and thus a blockade of autophagic flux. Finally, we also observed that VWK147 induces non-canonical LC3 lipidation, indicating that this compound exerts a broader effect on ion balance or pH of the endolysosomal system. VWK147 is a promising inhibitor that targets the C-terminal dimerization of HSP90 and simultaneously exhibits autophagy-modulating effects. This compound could potentially be an effective option for improving anti-cancer therapies and/or overcoming treatment resistance.

> **中文摘要：**
> 癌症成功治疗的主要障碍是针对治疗干预的耐药机制的存在或形成。在尿路上皮癌中，仍常规采用基于顺铂的治疗方案，而多条信号通路共同促成化疗耐药。自从发现热休克蛋白90（HSP90）作为潜在的癌症治疗靶点以来，各种HSP90抑制剂已经被开发并在临床试验中评估。然而，其疗效有限，主要原因是剂量相关毒性以及伴随诱导的细胞保护性热休克反应（HSR）。为避免此效应，研究者提出了针对HSP90 C端结构域（CTD）的抑制剂，这类药物不会引发HSR。此外，由于自噬与HSP90在蛋白稳态中协同作用，目前二者之间的相互调控也正受到关注；调节自噬可能有助于提高HSP90抑制剂的疗效。我们证明，第二代小分子抑制剂VWK147通过靶向HSP90 CTD二聚化，可诱导顺铂敏感型和顺铂耐药型尿路上皮癌细胞死亡。在这些细胞中，VWK147处理导致经典HSP90客户蛋白的不稳定，而不触发HSR。此外，我们观察到VWK147可使耐药性尿路上皮癌细胞重新对顺铂敏感，并且与mTOR抑制联合应用时，在顺铂敏感和耐药细胞中表现出协同致死作用，这与针对HSP90 N端的抑制剂17-AAG处理的结果不同。这种协同效应可能源于VWK147介导的晚期自噬事件抑制，从而阻断自噬流。最后，我们还观察到VWK147诱导了非经典的LC3脂化，提示该化合物对内体-溶酶体系统的离子平衡或pH具有更广泛的影响。VWK147是一种有前景的HSP90 C端二聚化抑制剂，同时具有调节自噬的作用，该化合物或可成为提高抗癌疗效及克服耐药的新选择。

### 第二部分 AI 大师评价

该研究聚焦于通过抑制HSP90 C端二聚化的新型小分子VWK147来克服顺铂耐药问题。作者系统评估了其在尿路上皮癌细胞中的作用机制，发现VWK147可独立诱导细胞死亡、破坏HSP90客户蛋白稳定性，并与mTOR抑制剂产生显著协同效应。其独特之处在于不激活热休克反应，同时能调控自噬过程，特别是阻断自噬流。研究揭示了HSP90与自噬间的新型作用联系，为开发低毒高效的抗耐药癌症治疗策略提供了创新方向，但仍需进一步验证其体内疗效与安全性。

---

## 38. 用于癌症纳米疫苗功能测试的先进人源免疫细胞–类器官共培养体系

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436389)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41436389
**DOI：** 10.1002/advs.202515199

### 第一部分 原文与翻译

**英文原标题：** Advanced Human Immune Cell-Organoid Co-Cultures for Functional Testing of Cancer Nanovaccines.

> **英文摘要：**
> Pancreatic ductal adenocarcinoma (PDAC) remains a major clinical challenge due to late detection and limited treatment responsiveness. To better evaluate complex immunotherapies in a human-relevant setting, we developed an integrated organoid-immune co-culture pipeline using PDAC patient-derived organoids (PDOs) and matched HLA immune cells. As a proof of concept, we assessed an MSLN-targeted nanovaccine (Mesovac), alone and in combination with FOLFIRINOX chemotherapy and Atezolizumab. We evaluated Mesovac across a multi-stage pipeline, including T-cell stimulation, ex vivo expansion, and PDO-immune co-cultures, to assess immune activation, specificity, and synergy with combinatorial treatments. MSLN-stimulated T-cells, derived from PDAC patients, showed increased IFN-γ production and selective infiltration into MSLN-expressing PDOs. Artificial antigen-presenting cells (aAPCs) boosted the expansion of reactive T-cells, enhancing antitumor responses. Notably, combining Mesovac with FOLFIRINOX and Atezolizumab maintained PD-L1+ T-cell levels and reduced cancer stem cells and aggressive PDAC subsets. Using this advanced in vitro workflow, we highlight that this platform, using human organoid-immune cell co-cultures, enables the evaluation of complex processes related to nanovaccine strategies that would not be possible in vivo.

> **中文摘要：**
> 胰腺导管腺癌（PDAC）由于晚期检测和有限的治疗响应性，仍然是一个主要的临床挑战。为在与人体高度相关的环境中更好地评估复杂的免疫治疗，我们开发了一种综合的类器官–免疫共培养流程，利用来自PDAC患者的类器官（PDOs）及其匹配的HLA免疫细胞。作为概念验证，我们评估了一种靶向MSLN的纳米疫苗（Mesovac），单独使用或与FOLFIRINOX化疗及Atezolizumab联合使用。我们在一个多阶段的流程中评估了Mesovac，包括T细胞刺激、离体扩增以及PDO–免疫细胞共培养，以检测免疫激活、特异性以及与联合治疗的协同效应。来自PDAC患者的MSLN刺激T细胞显示IFN-γ产量增加，并选择性地浸润表达MSLN的PDOs。人工抗原呈递细胞（aAPCs）促进了反应性T细胞的扩增，从而增强抗肿瘤应答。值得注意的是，Mesovac与FOLFIRINOX和Atezolizumab联合使用可维持PD-L1阳性T细胞水平，并减少癌症干细胞及侵袭性PDAC亚群。利用此先进的体外工作流程，我们强调该平台通过人源类器官–免疫细胞共培养，使得对纳米疫苗策略相关的复杂过程进行评估成为可能，而这些在体内难以实现。

### 第二部分 AI 大师评价

该研究建立了一个用于胰腺癌免疫纳米疫苗功能测试的高保真类器官–免疫细胞共培养体系，体现了精准医学与免疫工程的融合。通过MSLN靶向纳米疫苗Mesovac的多阶段验证，研究系统评估了免疫激活、特异性及与化疗和免疫检查点抑制剂的协同效应。结果显示该平台可重现患者来源T细胞的功能反应，并揭示其联合治疗的潜在增益机制。该方法的创新在于提供了一种可跨越体内实验限制的人源化体外评估模型，但未来仍需验证其在临床转化中的可行性与稳定性。

---

## 39. 癌症中的细胞毒性CD4+ T细胞：下一代抗癌免疫治疗的新兴靶点？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436233)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41436233
**DOI：** 10.1136/jitc-2025-013461

### 第一部分 原文与翻译

**英文原标题：** Cytotoxic CD4+ T cells in cancer: an emerging target for next-generation anticancer immunotherapy?

> **英文摘要：**
> Over the last decades, a growing number of distinct CD4+T helper cells has been identified and our understanding of CD4+T cell differentiation and function in various disease contexts has increased immensely. It has long been thought that the role of CD4+T cells in the tumor microenvironment (TME) was limited to coordinating the immune response by stimulating other immune cells and by secretion of cytokines with antitumor activity, while direct killing of tumor cells has been largely attributed to cytotoxic CD8+T cells. Notably, CD4+T cells with direct cytotoxic activity (CD4+CTLs) have been reported in the context of viral infections, autoimmune disorders, and more recently in patients with various cancer types. These cells have the ability to secrete cytotoxic molecules and kill target cells in a major histocompatibility complex (MHC) class II-dependent manner. In this review, we give an overview of phenotypical characteristics of CD4+CTLs in human cancers and the antitumor mechanisms employed by these cells. Further, we explore their role and clinical relevance in the context of cancer and describe how these cells may be used for the development of novel immunotherapeutic options to benefit patients with cancer with MHC class II-positive tumors.

> **中文摘要：**
> 在过去的几十年中，研究者鉴定出了越来越多的不同类型的CD4+辅助T细胞，我们对CD4+T细胞在各种疾病环境下的分化与功能的理解也有了极大的提升。长期以来，人们认为CD4+T细胞在肿瘤微环境（TME）中的作用主要是通过刺激其他免疫细胞及分泌具有抗肿瘤活性的细胞因子来协调免疫反应，而直接杀伤肿瘤细胞的功能主要归因于细胞毒性CD8+T细胞。值得注意的是，具有直接细胞毒活性的CD4+T细胞（CD4+CTLs）已在病毒感染、自身免疫性疾病以及近年来的多种癌症患者中被报道。这些细胞能够分泌细胞毒性分子，并以主要组织相容性复合体（MHC）Ⅱ类依赖的方式杀伤靶细胞。在本综述中，我们概述了人类癌症中CD4+CTLs的表型特征及其所采用的抗肿瘤机制。此外，我们还探讨了这些细胞在癌症中的作用及临床相关性，并阐述了它们如何被用于开发新型免疫治疗策略，以造福于MHCⅡ类阳性的癌症患者。

### 第二部分 AI 大师评价

本文综述聚焦于CD4+细胞毒性T细胞在肿瘤免疫中的新兴作用，挑战了传统上仅CD8+T细胞具有直接杀伤活性的认知。作者系统概述了CD4+CTL的表型特征、分子机制及其在多种癌症中的潜在意义。研究突出了其在MHCⅡ类阳性肿瘤中的治疗潜力，为开发下一代免疫治疗策略提供了新方向。文章的创新性在于重新定义CD4+T细胞的功能谱系，但当前研究仍受限于临床证据有限与机制尚未完全阐明。

---

## 40. Fc结构区增强型抗CTLA-4抗体Botensilimab联合抗PD-1抗体Balstilimab在治疗难治性卵巢癌患者中的研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41436232)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41436232
**DOI：** 10.1136/jitc-2025-013222

### 第一部分 原文与翻译

**英文原标题：** Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.

> **英文摘要：**
> BACKGROUND: Patients with platinum-resistant/refractory ovarian cancer (PROC) experience suboptimal outcomes, highlighting an immediate need for novel therapies. This phase 1b study investigated the safety and efficacy of botensilimab (BOT), a fragment crystallizable (Fc)-enhanced anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody with differentiated mechanisms of action from first-generation CTLA-4 inhibitors, plus balstilimab (BAL; anti-programmed cell death protein 1 antibody), in an expanded cohort of patients with treatment-refractory ovarian cancer.
> 
> METHODS: BOT was administered intravenously at 1 mg/kg or 2 mg/kg every 6 weeks in combination with BAL intravenously at 3 mg/kg every 2 weeks (up to 2 years). The primary objectives were to assess safety and tolerability. Efficacy end points included objective response rate (ORR), duration of response (DOR), and progression-free survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1. Overall survival (OS) was an exploratory end point.
> 
> RESULTS: Overall, 44 patients were evaluable for safety (with a median of 3 prior lines of therapy; median follow-up 9.6 months (range, 0.6-36.6)), and 35 for efficacy. The most common treatment-related adverse event was diarrhea/colitis (43%; 16% grade 3) with no treatment-related deaths. RECIST-confirmed ORR was 23% (8/35; 95% CI 10% to 40%; one complete (CR), seven partial responses (PRs)) and clinical benefit rate (CR, PR, or stable disease ≥24 weeks) was 31% (11/35; 95% CI 17% to 49%). Median DOR was 9.7 months (95% CI 2.8 to not reached (NR)), median PFS was 2.8 months (95% CI 1.4 to 5.5), median OS was 14.8 months (95% CI 12.1 to NR), and 12-month OS was 75% (95% CI 55% to 86%). Immune phenotypic analyses and biomarker data revealed significantly higher FcγRIIIA+CD11c+ cells and higher programmed death-ligand 1 expression in responding patients, a strong association between T-cell infiltrated tumors and clinical benefit, and differences in immune architecture across histologic subtypes.
> 
> CONCLUSION: The BOT/BAL combination demonstrated deep, durable responses and complete remissions in patients with treatment-refractory ovarian cancer where no standard treatments are currently available. RECIST under-represented clinical benefit with 11 patients achieving prolonged/clinically meaningful stable disease (or better) for ≥24 weeks. Toxicities were manageable and reversible. The encouraging clinical activity of BOT/BAL in heavily pretreated patients, as well as biomarker associations, warrants further investigation of this combination.

> **中文摘要：**
> 背景：铂耐药或难治性卵巢癌（PROC）患者疗效不佳，凸显出亟需新的治疗策略。本项Ib期研究评估了Botensilimab（BOT，一种Fc片段增强的抗细胞毒性T淋巴细胞相关抗原4（CTLA-4）抗体，其作用机制区别于第一代CTLA-4抑制剂）联合Balstilimab（BAL，抗程序性死亡蛋白1抗体）在治疗难治性卵巢癌患者中的安全性与疗效。
> 
> 方法：BOT以1 mg/kg或2 mg/kg剂量每6周静脉输注一次，与BAL 3 mg/kg每2周静脉输注（最长可至2年）联合应用。主要研究目标为安全性和耐受性评估。疗效终点包括依据实体瘤疗效评估标准（RECIST）V1.1的客观缓解率（ORR）、缓解持续时间（DOR）及无进展生存期（PFS）。总生存期（OS）为探索性终点。
> 
> 结果：共有44例患者纳入安全性分析（中位既往治疗线数3，中位随访9.6个月，范围0.6–36.6个月），其中35例可评估疗效。最常见治疗相关不良事件为腹泻/结肠炎（43%，其中3级16%），未见治疗相关死亡。RECIST确认的ORR为23%（8/35；95% CI 10%–40%；其中1例完全缓解（CR），7例部分缓解（PR）），临床获益率（CR、PR或稳定病情持续≥24周）为31%（11/35；95% CI 17%–49%）。中位DOR为9.7个月（95% CI 2.8–未达到），中位PFS为2.8个月（95% CI 1.4–5.5），中位OS为14.8个月（95% CI 12.1–未达到），12个月OS为75%（95% CI 55%–86%）。免疫表型及生物标志物分析显示，治疗应答患者体内FcγRIIIA+CD11c+细胞及PD-L1表达水平均显著升高，T细胞浸润肿瘤与临床获益呈强相关，不同组织学亚型之间的免疫结构亦存在差异。
> 
> 结论：在无标准治疗可选的治疗难治性卵巢癌患者中，BOT/BAL联合治疗显示出深度且持久的缓解，其中部分患者达到完全缓解。RECIST标准可能低估了临床获益，共有11例患者实现临床意义重大的持久疾病稳定（≥24周或更久）。毒性反应总体可控且可逆。BOT/BAL联合方案在多线治疗后患者中的令人鼓舞的活性及其生物标志物关联性，值得进一步研究。

### 第二部分 AI 大师评价

该研究是一项针对铂耐药或难治性卵巢癌的Ib期临床试验，评估Fc增强型抗CTLA-4抗体Botensilimab联合抗PD-1抗体Balstilimab的安全性与疗效。结果显示该组合在高度预处理的患者中实现了较高的客观缓解率和长期临床获益，且不良反应可控。研究中的免疫学分析揭示了特定细胞亚群与疗效的相关性，为联合免疫治疗在卵巢癌中的机制探索提供了新依据。尽管样本量有限且为早期研究，但其疗效信号与生物标志物发现具有重要的临床转化潜力。

---

## 41. 最后的沉默

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41435209)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41435209
**DOI：** 10.1200/JCO-25-01709

### 第一部分 原文与翻译

**英文原标题：** Final Silence.

> **英文摘要：**
> A physician confronts the burden of silence in the care of the dying.

> **中文摘要：**
> 一位医生在照护临终患者的过程中，面对沉默所带来的沉重负担。

### 第二部分 AI 大师评价

本文以高度凝练的语言探讨了医生在临终关怀中所承受的情感与伦理压力。作者通过“沉默”这一隐喻性主题，呈现医患间未言之痛的沉重与无奈。尽管篇幅短小，但传达了关于沟通、情感共鸣与职业孤立的深刻思考。文章的创新在于以叙事视角揭示医学人文的内核，而局限性在于缺乏实证数据支撑。

---

## 42. 自动化淋巴结及淋巴结外扩展评估可改善口咽癌的风险分层。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41435207)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41435207
**DOI：** 10.1200/JCO-24-02679

### 第一部分 原文与翻译

**英文原标题：** Automated Lymph Node and Extranodal Extension Assessment Improves Risk Stratification in Oropharyngeal Carcinoma.

> **英文摘要：**
> PURPOSE: Extranodal extension (ENE) is a biomarker in oropharyngeal carcinoma (OPC) but can only be diagnosed via surgical pathology. We applied an automated artificial intelligence (AI) imaging platform integrating lymph node autosegmentation with ENE prediction to determine the prognostic value of the number of predicted ENE nodes.
> 
> MATERIALS AND METHODS: We conducted a multisite, retrospective study of 1,733 OPC patients with pretreatment computed tomography who underwent definitive radiation therapy across three institutions. Malignant lymph nodes were segmented using a validated deep learning auto-segmentation model, and segmented lymph nodes were sequentially processed with a validated ENE prediction model to calculate number of nodes with AI-predicted ENE (AI-ENE) per patient. We evaluated associations of AI-ENE with disease outcomes using site-stratified, multivariable Cox regression, adjusting for human papillomavirus (HPV) status, smoking pack-years, tumor and nodal stage, age, and sex. We evaluated risk-stratification improvement when incorporating AI-ENE into the Radiation Therapy Oncology Group (RTOG)-0129 risk groupings and derived American Joint Committee on Cancer (AJCC) 8th edition staging with Uno C-indices and decision curve analyses.
> 
> RESULTS: Overall, median AI-ENE node number was 1 (range, 0-6). AI-ENE node number was independently associated with poorer distant control (DC; hazard ratio [HR], 1.44 [95% CI, 1.23 to 1.69];  < .001) and overall survival (OS; HR, 1.30 [95% CI, 1.16 to 1.46];  < .001). Increasing AI-ENE node number was incrementally associated with worse outcome, particularly DC ( < .001). C-indices improved in the external data set when incorporating AI-ENE into RTOG-0129 groupings (OS: 0.70  0.65; DC: 0.65  0.57) and AJCC-8 stage (OS: 0.75  0.70; DC: 0.72  0.67;  < .001 for each). The largest improvements were observed among HPV-negative patients (C-index: +15% for OS, +14% for DC).
> 
> CONCLUSION: Automated, AI-ENE node number is a novel risk factor for OPC that may better inform pretreatment risk stratification and decision-making.

> **中文摘要：**
> 研究目的：淋巴结外扩展（ENE）是口咽癌（OPC）的一个生物标志物，但目前只能通过手术病理进行诊断。本研究应用一个自动化人工智能（AI）影像平台，将淋巴结自动分割与ENE预测相结合，以确定预测的ENE淋巴结数量的预后价值。
> 
> 研究材料与方法：我们在三家机构开展了一项多中心回顾性研究，纳入了1,733例接受根治性放疗且术前行计算机断层扫描（CT）检查的OPC患者。恶性淋巴结通过经验证的深度学习自动分割模型进行分割，随后使用经验证的ENE预测模型对分割的淋巴结进行逐步处理，计算每位患者由AI预测出的ENE结节（AI-ENE）数量。我们采用分中心分层的多变量Cox回归分析，调整人乳头瘤病毒（HPV）状态、吸烟包年数、肿瘤及淋巴结分期、年龄及性别等协变量，评估AI-ENE与疾病结局的关联。进一步将AI-ENE纳入放射治疗肿瘤学组（RTOG）0129风险分层及第8版美国癌症联合委员会（AJCC）分期体系中，利用Uno一致性指数（C-index）及决策曲线分析评估风险分层的改进情况。
> 
> 研究结果：总体而言，AI-ENE结节数的中位数为1（范围0–6）。AI-ENE结节数与较差的远处控制（DC；风险比[HR]，1.44 [95% CI，1.23–1.69]；P < .001）及总体生存（OS；HR，1.30 [95% CI，1.16–1.46]；P < .001）独立相关。AI-ENE结节数增加与较差的结局呈递增关联，尤其在DC方面（P < .001）。当将AI-ENE纳入RTOG-0129风险分组时，外部数据集中的C指数提高（OS：0.70 vs 0.65；DC：0.65 vs 0.57）；纳入AJCC第8版分期时，C指数亦提高（OS：0.75 vs 0.70；DC：0.72 vs 0.67；各项P < .001）。最大改进观察于HPV阴性患者（C指数：OS提升15%，DC提升14%）。
> 
> 结论：自动化AI预测的ENE结节数量是OPC的新型风险因子，可在治疗前风险分层与临床决策中提供更准确的信息。

### 第二部分 AI 大师评价

本研究利用人工智能影像平台，首次自动化整合淋巴结分割和ENE预测，提出AI预测ENE结节数作为口咽癌的新预后指标。多中心回顾性分析显示，该指标独立关联较差的远处控制和总体生存，并可显著提升现行RTOG及AJCC分期体系的风险判别力。研究方法扎实，样本量充足，具备较强的外部验证能力，其创新在于将AI定量影像特征直接纳入临床风险模型。然而，研究仍为回顾性设计，未来需前瞻性验证其临床可行性与决策效益。

---

速递结束，祝您工作愉快！